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Background and aims: Hypertension poses a great challenge to public health and is a major 
reason for hospitalisation and death. In Mozambique, there are currently very low levels in 
the detection, treatment and the control of the condition. However, data on target-organ 
damage and associated clinical conditions is lacking. We therefore aimed at characterising 
the clinical profile of patients with severe hypertension, describing the pattern of target organ 
damage and determining the outcomes at 6-month follow-up. 
Methods: We designed a prospective descriptive cohort study to assess adult patients with 
severe and complicated hypertension defined according to the Joint National Committee VII 
guidelines. The study was conducted from July 2015 to May 2017 at Mavalane General 
Hospital in Maputo-Mozambique. Patients were characterized through physical examination, 
laboratory profile, electrocardiography, and echocardiography, and followed for six months to 
assess occurrence of complications such as hypertensive heart failure, stroke, renal failure, 
hospital admission and death. Data were analysed using SPSS software version 20.0. The 
study was approved by the National Bioethics Committee for Health of Mozambique. 
Results: We studied 116 subjects (111 [95.7%] black; women 81 [70%]). Women were 
slightly younger than men 57 vs 59 years respectively; 18 of 116 (15.5%) patients were 
younger than 44 years. The risk profile of the studied population included obesity (46; 
42.5%); dyslipidaemia (59; 54.1%); diabetes (10; 8.6%) and smoking (8; 6.9%).The baseline 
mean values recorded for systolic and diastolic blood pressure were 192.3 ± 23.6 and 104.2 
± 15.2, respectively. Most subjects (93; 80.2%) reported being on antihypertensive treatment 
at the entry, but only 37.4% had BP controlled at the end of follow-up. The most frequent 
target-organ damage were left atrial enlargement in 91 (88.3%) with atrial fibrillation in 9 
(7.9%); left ventricular hypertrophy in 57 (50.4%); hypertensive retinopathy in 30 (26.3%) 
and renal damage in 29 (25.7%) subjects. Major events during 6-month follow-up were 
hospitalisations (12; 10.3%) and death (10; 8.6%). Renal damage (4.2%), stroke (3.4%) and 
heart failure (1.7%) were the most common complications occurring over the follow up 
period. 
Conclusion: Severe and complicated hypertension affects young people with higher 
incidence of obesity, diabetes and smoking than that found in general population. High 
occurrence of target organ damage is found at baseline, particularly heart damage, renal 
lesion and stroke. On follow up, severe hypertension is associated with high number of 
hospitalisations and high case-fatality rate. Moreover, renal damage, stroke and 
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hypertensive heart disease were common complications on follow up. Further research is 
needed to understand the determinants of these poor outcomes. 






































1.1.1. Epidemiology of Hypertension  
Hypertension or high blood pressure (HBP) is a public health problem, with high prevalence 
in the world (Lim et al., 2012; NCD risk factor collaboration, 2017). It is the most frequent 
cause of Non-Communicable Diseases (NCDs) and the major risk factor for most common 
severe complications such as stroke, acute myocardial infarction and kidney disease (WHO 
2009; He et al., 1997; Whelton, 1994). The World Health Organization (WHO) estimated that 
approximately 25% of the world’s adult population had hypertension in 2000 and is predicted 
to increase to 1.56 billion in 2025. In addition, it has been suggested that there is no 
difference in the overall prevalence of hypertension in men and women worldwide and that 
such prevalence consistently increases with age in all regions (WHO Report, 2002). 
The importance of systemic hypertension as a major cause of common serious disease has 
been recognized in most Western countries for over 50 years (Harrington et al., 1959). 
Before this, malignant hypertension was a frequent reason for hospital admission and a 
common cause of sudden death. Safe and effective anti–hypertensive drug treatments first 
emerged in the 1960s and were shown to dramatically improve the prognosis associated 
with malignant hypertension (Yu et al., 1986). Thereafter, blood pressure reduction 
treatments were provisioned to a larger group of patients who had severe cardiovascular 
disease (CVD), such as cerebrovascular accident and coronary heart disease. This 
importantly contributed to a reduction in the stroke and coronary heart disease death rates 
experienced in most Western populations (Unal et al., 2005). However, in contrast to higher-
income countries, the burden of hypertension and hypertension– related diseases increased 
in lower–income countries. This has been majorly attributed to an increase in urbanization 
(Singh et al., 2000). 
HBP remains a public health problem, with high prevalence in the world and its incidence 
increases with age. About a third of adults (30-45% of the general population) have 
hypertension (Mancia et al., 2013). This is usually asymptomatic, so its diagnosis and 
treatment are often overlooked. The shortage of health workers in endemic areas also limits 
the diagnosis and proper management of its complications (Kider et al., 2011).  
Factors that indicate a worse HBP prognosis are the black race, young age, being male, 
having severe hypertension, smoking, diabetes mellitus, dyslipidaemia, obesity, premature 
CVD history and evidence of target organ damage (Weber et al., 2014). 
4 
 
Moreover, hypertension (HTN) is a well-known risk factor for heart attacks and strokes, and 
it is associated with left ventricular hypertrophy (LVH), proteinuria and kidney failure, 
retinopathy and vascular dementia, which fall under the concept "target organ damage" 
(TOD) (Nadar et al., 2006). 
National surveys to assess the prevalence of HTN were conducted in the United States, 
Canada and Europe (Germany, Finland, Sweden, England, Spain, Italy) in the 1990s (survey 
sizes ranged from 1800 – 23100). Different prevalence was found in these countries: Italy: 
37.7%, Sweden: 38.4%, England: 41.7%, Spain: 46.8%, Finland: 48.7%, Germany: 55.3%, 
United States: 27.8% and Canada: 27.4%. The prevalence of HTN for the European region 
was in average 44.2%, while that for the whole of North America was 27%. In these surveys, 
age-specific HTN prevalence demonstrated a significant peak similarly to systolic blood 
pressure (SBP) for individual countries. A higher intercept and slope were observed in 
Europe, compared to Canada and the United States. For example, the prevalence was 14% 
in North American countries and 27% in Europe for the age group 35-44 years, and this 
increased to 53% and 78% in America and Europe respectively, among patients aged 65-74 
years (Wolf-Maier et al., 2003). 
Hypertension is one of the main reasons of demand for primary health care in African 
countries. In Nigeria, with the current definition of high blood pressure, according to the 
Seventh Joint National Committee on Prevention, Detection, Evaluation and Treatment of 
High Blood Pressure (JNC VII) guidelines, 20 to 25% of adult Nigerians affirmed as being 
hypertensive (Ogah, 2006). A systematic review of 25 studies (each containing more than 
400 subjects) from 10 sub-Saharan African countries (Nigeria, Tanzania, South Africa, 
Ghana, Sudan, Cameroun, Liberia, Eritrea, Senegal and Gambia) revealed a prevalence of 
HTN ranging from 13 – 48% and having a rural to the urban gradient (Addo et al., 2007; 
Stewart et al., 2011). In cross-sectional surveys of HTN in four rural and urban communities 
in Sub-Saharan Africa (SSA), the age-standardized prevalence of HTN was as follows: Rural 
Nigeria (19.3%), rural Kenya (21.4%), urban Tanzania (23.7%) and in urban Namibia 






Figure 1: Map showing the change on hypertension prevalence in adults 20 years and older 
in 2000-2010 by country (Mills et al., 2016). 
 
 
Figure 2: Map of the prevalence of raised blood pressure, aged 18+, 2014 (age 






Figure 3: Map of Sub-Saharan Africa (SSA) showing the crude prevalence of hypertension 
in 38 recent studies in different parts of SSA, adapted by Map of the crude prevalence of 
HTN in 38 recent studies in different parts of Sub-Saharan Africa (Ogah and Rayner, 2013). 
 
1.1.1.1. Hypertension in Mozambique 
The first Stepwise Approach to Chronic Disease Risk Factor Surveillance (STEPS) following 
the WHO recommendations in Mozambique was conducted in 2005 aiming to determine the 
prevalence, awareness, treatment and control of HTN in urban and rural populations. The 
study included a representative sample population of 3,323 individuals aged between 25 and 
64. The prevalence of HTN was 33.1% (women 31.2%, men 35.7%). Most participants (3/4) 
had at least 45 years of age and approximately 10% had more than 54 years of age. Of the 
individuals with HTN 14.8% (women 18.4%, men 10.6%) were aware of their disease; 51.6% 
(women 61.1%, men 33.3%) of those who had knowledge of their condition were under 
treatment, and only 29.9% (women 31.2%, men 28.7%) of those treated had a controlled 
blood pressure (BP). In women, HTN was more frequent in urban areas when compared 
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with rural areas (41% vs 26.8%, respectively). Diastolic blood pressure (DBP) was higher in 
the urban area in both sexes; there was no significant difference in SBP. Systolic BP and 
DBP increased with age in both sexes (Damasceno et al., 2009). 
 
Evidence of the high burden of complications related to the lack of control of HTN has been 
obtained from a study conducted in city of Maputo-Mozambique. This study showed a yearly 
incidence of stroke of 148.7 per 100,000 populations and 260.1 per 100,000 in the 
population with an age above 25 years (Damasceno et al., 2010), considerably higher than 
123.9 per 100,000 found in the UK (Wolfe et al., 2000). HTN was the most important risk 
factor in these patients and determined high mortality rate (in-hospital mortality: 33.3%, 28 
days of mortality: 49.6%), especially through haemorrhagic stroke associated with HTN. 
 
1.1.2. Concepts on Hypertension 
According to WHO, hypertension is defined as systolic blood pressure ≥ 140 mmHg and/or 
diastolic blood pressure ≥ 90 mmHg and/or use of anti-hypertensive drugs; the same 
classification is used in all age group subjects (WHO, 2009; JNC 6, 1997; Carretero et al., 
2000). 
The cut-off mark for the definition of HTN has evolved over time. In 1980, HTN was defined 
when blood pressure was higher than systolic 160 mmHg and/or diastolic 95 mmHg. 
Currently, the definition most commonly used is that of the JNC7 which defines three levels 
of elevated blood pressure (Chobanian et al., 2003; JNC7 Report, 2004). Stage 1 
hypertension which is defined as SBP between 140-159 mmHg or DBP between 90-99 
mmHg. Stage 2 HTN, on the other hand, refers to all levels of SBP ≥ 160 mmHg and/or DBP 
≥ 100 mmHg. JNC7 also introduced the classification of blood pressure between 120 mmHg 
to 139 mmHg SBP or 80 to 89 mmHg DBP as pre-hypertension, based on the risk of 
progression and associated cardiovascular (CV) risk. Patients with blood pressure in the 
130/80 to 139/89 mmHg range have been found to be at twice the risk of developing HTN, 
compared with those with lower values (Vasan et al., 2000). 
The risk of clinical events associated with HTN is determined by the level of BP and also by 
the presence of TOD. Equally important, is the presence of established cardiovascular 
disease (ischaemic heart disease or heart failure, stroke, peripheral vascular disease) or 
concomitant disease associated with high cardiovascular disease risk, e.g. diabetes or 
chronic kidney disease or the calculated cardiovascular risk (estimated from factors such as 




1.1.2.1. Definitions and Classification  
According to WHO the following definitions are is used for HBP: 
 Mild hypertension (Grade 1) is defined by values between 140-159 mm Hg SBP 
and 90-99 mm Hg DBP. 
 Moderate hypertension (Grade 2) is defined by values between 160-179 mm Hg 
SBP and 100-109 mm Hg DBP. 
 Severe hypertension (Grade 3) is defined as SBP values equal to or greater than 
180 mm Hg and/or DBP equal to or higher than 110 mmHg; or SBP ≥ 160 mmHg and 
DBP values ≥ 100 mm Hg in the presence of 1 or 2 risk factors or target organ 
damage (Chobanian et al., 2003; James et al., 2014). 
 Complicated hypertension is defined as values of blood pressure above 140 mm 
Hg SBP and 90 mm Hg DBP in the presence of injury or impairment in the function of 
a target organ such as the brain, arteries, heart, eyes and kidneys. 
 Resistant or refractory hypertension is defined as blood pressure that remains 
above goal in spite of the concurrent use of 3 antihypertensive agents of different 
classes. Ideally, one of the 3 agents should be a diuretic and all agents should be 
prescribed at optimal dose amounts. As defined, resistant hypertension includes 
patients whose blood pressure is controlled with use of more than 3 medications. 
That is, patients whose blood pressure is controlled but require 4 or more 
medications to do so should be considered resistant to treatment (Calhoun et al., 
2008). Multiple factors such as the lack of adherence to treatment recommendations, 
use of drugs in insufficient doses, drug interactions, the presence of sodium overload 
(high volume), associated clinical conditions, pseudo-hypertension or hypertension 
white coat must be considered when suspecting a resistance to treatment. Finally, 
possible causes of secondary hypertension should be disposed to consider the 












Table 1: Definitions and classification of office blood pressure levels (Mancia et al., 2013), 
European Society of Hypertension (ESH) and European Society of Cardiology Guidelines 
(ESC) for the management of arterial hypertension - The Task Force of the management of 





Several factors contribute to the high prevalence of HTN including high salt and fat intake, 
poor nutrition (e.g. low consumption of fruits and vegetables), overweight and obesity, 
excessive consumption of alcohol, physical inactivity, ageing, genetic factors, psychological 
stress and socioeconomic determinants (WHO Report, 2014). Although the exact cause of 
HTN is unknown in the majority of cases, these risk factors are involved in its pathogenesis.  
Modifiable risk factors for HTN include the following: obesity (defined as BMI ≥ 30 kg / m², or 
central or abdominal obesity in men: ≥ 102 cm, and women: ≥ 88 cm), sedentary habits, 
dietary habits (excessive consumption of salt), alcoholism, dyslipidaemia, and fasting plasma 
glucose or abnormal glucose tolerance test. On the other hand the non-modifiable risk 
factors include family history (early history of CVD, HTN, diabetes mellitus, obesity and 
dyslipidaemia in the family), age (men ≥ 55 years, women ≥ 65 years), sex (predominantly 
male), low birth weight, and black race (Mancia et al., 2013; Weber et al., 2014).  
Several risk factors (RF) for HTN has been observed as more common in developing 
regions than in developed regions in the world (Ibrahim and Damasceno, 2012). The high 
prevalence of HTN is possibly caused by urbanization, ageing of population, changes in 
Category  Systolic BP (mmHg)  Diastolic BP (mmHg) 
Optimal < 120 And < 80 
Normal 120 – 129 and/or 80 – 84 
High Normal 130 – 139 and/or 85 – 89 
Grade 1 hypertension 140 – 159 and/or 90 – 99 
Grade 2 hypertension 160 – 179 and/or 100 – 109 
Grade 3 hypertension ≥ 180 and/or ≥ 110 
Isolated systolic hypertension  ≥ 140 And < 90 
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dietary habits, and social stress (Ibrahim and Damasceno, 2012; Addo et al., 2007; 
Agyemang et al., 2005; Van der Sande, 2003; Mosley et al., 1993). The risk factors 
(modifiable and non-modifiable RF) are described in the table below (Table 1.2). 
Approximately 95% of the adult population with high blood pressure have primary HTN 
(commonly known as essential hypertension). It is thought that genetic and environmental 
factors are involved in the genesis of essential hypertension. Some genetically related 
factors include the inappropriately high activity of the renin-angiotensin-aldosterone system, 
the sympathetic nervous system and the susceptibility to the effects of dietary salt could play 
a role; and behavioural factors include sedentary lifestyle, inappropriate diet (high levels of 
salt and fat intake), and excessive consumption of alcohol also play a significant role. The 
smoking habit is a major risk factor for the complication of HTN, like ischaemic heart disease 
and stroke. 
Furthermore, a frequent cause of HTN is the stiffening of the aorta with increasing age. This 
type of HTN is referred to as isolated or predominant systolic HTN and is marked by high 
SBP (often with normal DBP). It is mainly found in people with an advanced age (Weber et 
al., 2014). 
 
Table 2: High-Risk Features in HTN (Adapted from Kidder et al., 2011, Chronic Care 
Integration for Endemic Non-Communicable Diseases). 
 
High-risk feature Points 
Diagnosis of diabetes 2 
Diagnosis of renal failure (creatinine ≥ 100umol/L) 2 
Age ≥ 65 years 1 
BMI ≥ 25 kg/m2 1 
Tobacco smoking 1 
A total of 2 or more points is considered high risk and warrants more aggressive treatment. 
 
 
In a small number of HTN cases, about 3-5%, the aetiology of the rise in BP can be 
diagnosed and sometimes treated. This type of HTN can be suspected if HBP is very high 
and difficult to control, or has a sudden onset in a previously normotensive patient. The most 
common causes of secondary HTN are chronic kidney disease (CKD), renal artery stenosis, 
excessive aldosterone secretion, Cushing's syndrome, pheochromocytoma, thyroid disease 
and sleep apnoea. Intake of certain drugs, such as nonsteroidal anti-inflammatory, tricyclic 
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and other types of anti-depressants, previous high-dose oral contraceptives, anti-influenza or 
cold medications (e.g.: pseudoephedrine), migraine medications, cyclosporine and 
erythropoietin, can also cause HTN. Drugs like cocaine and herbal medicinal products can 
increase BP. Pregnancy HBP, aortic coarctation and aortic disease, renin-producing 
tumours, acromegaly, carcinoid syndrome and hyperparathyroidism are also causes of 
raised BP (Mancia et al., 2013; Weber et al., 2014). 
 
1.1.2.3. Assessment of HBP and Stratification of total cardiovascular risk 
Most patients with HTN have other RF for chronic diseases, including dyslipidaemia, hyper-
glycaemia or diabetes, a family history of premature cardiovascular events, obesity, smoking 
and alcohol habits (Weber et al., 2014). Specific behaviours such as tobacco use, physical 
inactivity, poor diet and alcohol abuse, can lead to key metabolic changes, which are RF for 
increased blood pressure, overweight/obesity, hyperglycaemia and hyperlipidaemia (WHO, 
2008). There is a close relationship between BP levels and the risk of cardiovascular events, 
cerebrovascular disease and renal disease. The chances of these events occurring is 
reduced with blood pressure levels below 115/75 mmHg. Above these values for each 
increase of 20 mmHg SBP or 10 mmHg DBP, the risk of cardiovascular events and stroke 
doubles (Chobanian et al., 2003). Each 20 mmHg increase in SBP in the range of 115 – 185 
mmHg doubles the risk of coronary heart disease and stroke mortality (Lewington et al., 
2002). HTN has also been found to be a causal factor in at least 70% of cerebrovascular 
accident mortality (Healey et al., 2016), and persons with normal blood pressure have about 
half the lifetime stroke risk compared to those with HTN (Bronner et al., 1995; Wolf et al., 
1991). Similarly, the incidence of the end-stage renal disease has been found to increase in 
parallel with systolic blood pressure. When normal systolic blood pressure of less than 
120mmHg is compared with a systolic blood pressure of 140-159mmHg, the relative risk of 
end–stage renal disease is increased by three-fold and for systolic blood pressure of 160- 
179 mmHg, end-stage renal disease risk increases by six-fold (Klag et al., 1996). Moreover, 
the association between HTN and cerebrovascular disease is double of that of cholesterol-
CVD relationship (Lewington et al., 2002; Joint National Committee on Prevention, 
Detection, Evaluation and Treatment of High Blood Pressure 1997). Finally, a relatively small 
decrease in systolic blood pressure (as low as 10 mmHg) has been shown to be associated 
with a 25% - 30% lower fatal stroke rate (Staessen et al., 2001). 
Based on the approximate relation concerning BP levels and the occurrence of CV events, 
stroke and renal disease, the total cardiovascular risk can be stratified taking all RF into 




Table 3: Stratification of total CV risk in categories of low, moderate, high and very high risk 
according to SBP and DBP and prevalence of RFs, asymptomatic OD, diabetes, CKD stage 
or symptomatic CVD (Mancia et al., 2013). 
BP= blood Pressure; CKD= chronic kidney disease; CVD= cardiovascular disease; diastolic blood 
pressure; HTN= hypertension; OD= organ damage; RF= risk factor; SBP= systolic blood pressure. 
 
1.1.3. Clinical Evaluation 
The evaluation of a patient with HTN at baseline should include the following: (1) HTN 
diagnosis should be confirmed, (2) secondary causes of HTN should be detected, and (3) 
the risk of cardiovascular disease, organ damage and concomitant clinical conditions should 
be assessed. This calls for BP measurement, personal medical history, family history, 
physical evaluation, laboratory investigations and further diagnostic exams (Mancia et al., 




organ damage or 
disease 
High Normal  
SBP 130 – 
139 or DBP 
85 – 89 
Grade I HTN 
SBP 140 – 159 
or DBP 90 – 99 
Grade 2 HTN 
SBP 160 – 179 
or DBP 100 – 
109 
Grade 3 
SBP ≥ 180 or 
DBP ≥ 110 
No other RF  Low risk  Moderate risk High risk 
1 – 2 RF Low risk Moderate risk Moderate to High 
Risk 
High risk 





High risk High risk 




High risk High risk Very High risk 
Symptomatic CVD, 





Very High risk Very High risk Very High risk 
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Most patients with HBP will be asymptomatic. The anamnesis should explore the previous 
diagnosis of HTN or antihypertensive treatment, occurrence of stroke, Coronary Artery 
Disease (CAD), Heart Failure (HF), kidney disease such as polycystic kidney and CKD, 
Diabetes Mellitus (DM), Sleep apnoea, HTN in pregnancy and postpartum and other risk 
factors such as family history of HTN, DM, dyslipidaemia, microalbuminuria, hyperuricemia, 
tobacco and drug history. 
The white coat effect should be considered when first assessing the patient and if in doubt, 
assessment of BP outside the clinic or ambulatory blood pressure monitoring for 24hours 
(ABPM) must be considered. Factors that may affect BP include posture, breathing, emotion, 
exercise, alcohol, tobacco and other drugs, temperature, pain, meals, and bladder distension 
(Weber et al., 2014; Mancia et al., 2013; Chobanian et al., 2003). Additionally, BP should be 
measured with appropriately size cuffs (eg: large cuffs for persons with large arms) to avoid 
over diagnosis (Campbell et al., 2015).  
High blood pressure/severe HTN without treatment can lead to stroke, hypertensive 
retinopathy, dementia, arteriosclerosis, HF, heart attack and kidney failure, conditions that 
are grouped under the term target organ damage (Nadar et al., 2006). People with HTN do 
not often report or demonstrate any apparent symptoms until they develop TOD (WHO, 
2013; WHO, 2007). Therefore, pro-active and cost-effective approaches must be put in place 
for early detection of HTN and TOD. It has been shown that targeted screening for 
assessment of total CV risk with BP measurement (and fast blood sugar testing) is more 
cost effective than screening the whole population for a single risk factor, and is more likely 
to identify individuals at high CV risk for lower cost (Lawson et al., 2010; Baker et al., 2013). 
To diagnose TOD and concomitant or associated clinical conditions (ACC), several 
diagnostic tests can be used namely funduscopic, electrocardiography, laboratory tests 
(blood sample and dipstick urine), home and 24-h ambulatory BP monitoring, 
echocardiography, exercise test, ultrasound of the carotid arteries, renal ultrasound and 
magnetic resonance imaging. 
 
1.1.3.1. Funduscopic Examination 
The funduscopic examination is part of a neurological examination that is indicated when 
suspected of hypertensive retinopathy in patients with severe or resistant hypertension. 
Funduscopic examination is important to detect haemorrhage, exudates and papilledema, 
which is associated with an elevated CV risk (Mancia et al., 2013). Hypertensive retinopathy 
is classified into 4 grades successively minimal narrowing of the retinal arteries, sclerosis 




Table 4: Keith-Wagener-Barker (KWB) classification criteria of hypertensive retinopathy 
(Keith et al., 1974). 
GRADE DESCRIPTION 
GRADE 1 Slight narrowing, sclerosis and tortuosity of the retinal arterioles; 
Frequently is asymptomatic and associated with mild HTN 
GRADE 2 Narrowing is more visible, focal constriction, sclerosis and 
arteriovenous nicking; elevated BP and more sustained; few, if any, 
symptoms referable to BP 
GRADE 3 Retinopathy (cotton-wool) patches, arteriosclerosis, haemorrhages; 
elevated BP and more sustained; headaches, vertigo and 
nervousness; mild impairment of target organs function (e.g. brain, 
heart and kidneys) 
GRADE 4 Neuroretinal oedema, including papilledema; Siegrist streaks, 
Elschnig spots; BP constantly high; headaches, asthenia, loss of 
weight, dyspnoea and visual disturbances; mild-severe impairment of 
cerebral, cardiac and renal function 
 
Grade I: It is asymptomatic, non-malignant, mild HTN, and slight narrowing, focal 
constriction, sclerosis and arteriovenous nicking; BP is elevated and more sustained; Grade 
II: Little, or no symptoms related to BP and arteriovenous nipping and non-malignant 
retinopathy, arteriosclerosis, haemorrhages, hard exudation and cotton-wool spots; Elevated 
BP; Grade III: Cotton-wool patches, arteriosclerosis, haemorrhages; elevated BP; 
headaches, vertigo and nervousness; mild impairment of target organs function (e.g. brain, 
heart and kidneys); Grade IV: Mild and/or severe impairment of cerebral, cardiac and renal 
functions and malignant and neuroretinal oedema (papilledema, Siegrist streaks, Elschnig 
spots); BP persistently elevated; headaches, asthenia, loss of weight, dyspnoea and visual 
disturbances; This stage is malignant (Wong et al., 2004; Walsh, 1982; Keith et al., 1974). 
 
1.1.3.2. Electrocardiography  
A 12-lead electrocardiography (ECG) should be done routinely in all patients with 
hypertension (Chobanian et al., 2003). The ECG helps in identifying ischemia conduction 
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abnormalities (former myocardial infarction), as well as left atrial dilatation and left ventricular 
hypertrophy (LVH), which are evidence of TOD and indicate the need of the adequate 
control of  BP. There are several criteria used for the diagnosis of LVH, from the simplest to 
the most complex. ECG also assists in identifying ischemia conduction alterations, left atrial 
enlargement and cardiac arrhythmias such as atrial fibrillation (Mancia et al., 2013; Kirchhof 
et al., 2017), which are markers of heart damage. 
In practice, the most used criteria for LVH are the Sokolow-Lyon index (SV1 + RV5 > 3.5 
mV, the modified Sokolow-Lyon index (largest S-wave + largest R-wave> 3.5 mV), Romhilt-
Estes and Cornell voltage QRS duration product (> 244mV*ms) [Povoa et al., 2008; Mancia 
et al., 2013]. The following are used as electrocardiographic signs of LVH: Increased 
amplitude of the QRS complex; Increased Complex QRS duration in the left precordial leads 
(QRS ≥ 0:09 sec); Electrical QRS axis deviation to the left ≥ -30º; Increased left atrial 
appendage (Morris signal); T wave flat, negative or biphasic in D1, V5; Delay in the onset of 
intrinsic deflection; S waves deep in the right precordial leads; Abnormality of ventricular 
repolarization pattern type strain; Bad prognosis: ST segment depression and negative T 
wave; QT interval shows greater dispersion as ventricular mass increases. The Sokolow-
Lyon criteria, one of the oldest and still widely used criteria, consists on the addition of the S 
wave amplitude in lead V1 with the R-wave in lead V5 or V6 (always the larger of the two). If 




Echocardiography is more sensitive and sometimes more specific than electrocardiography 
in the identification of LVH and is useful in diagnosing CV and renal risk (Reichek et al., 
1981; Levy et al., 1990; Tsioufis et al., 2010; Mancia et al., 2013).  It may, therefore, help in 
the more precise stratification of the overall risk and in determining therapy (Cuspidi et al., 
2002).  
Despite heart ultrasound being a tool with good sensitivity and specificity, high cost and low 
availability limit its use in large-scale in resource-constrained settings. However, in parts of 
the world such Mozambique, where there seems to be a high incidence of LV dysfunction 
related to uncontrolled severe HBP, it can be of great use. With the reduction in the cost of 
this technique and the availability of portable and battery powered devices, its use may 
increase in low-income settings. Focused or Abbreviated ultrasound collecting data on 
interventricular septal thickness at end diastole (IVSd), the posterior wall thickness at end 
diastole (PWD), end diastolic diameter and end systolic diameter, may be very important in 
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this context (Mancia et al., 2013). Data on valve mobility, LV filling pattern (E and A waves) 
and the presence of arrhythmia may further help to manage the patients.  
Cardiac ultrasound is also used for quantification of the ejection fraction (EF) in patients with 
suspected HF, although this test is not routinely in all hypertensive patients.  
HTN is associated with abnormalities of LV relaxation and filling, currently defined as 
diastolic dysfunction. Moreover, HTN induced diastolic dysfunction is often linked with 
concentric geometry and can induce symptoms and/or signs of HF, even when EF is still 
normal (HF with preserved EF) [Hogg et al., 2004; Mancia et al., 2013]. 
 
1.1.3.4. 24-h ambulatory BP monitoring 
When there is doubt regarding BP values in the clinic, home and 24-h ambulatory BP 
monitoring are recommended. These approaches allow us to obtain various measurements 
of BP throughout the day (during the daily routine activities and at night) in a non-hospital 
environment. In clinical practice, 24-h ambulatory BP monitoring measurements may be 
done at 15 minutes intervals during the day and every 30 minutes overnight/bed time 
(Mancia et al., 2013).  
ABPM is strongly related preclinical TOD than over the desk measurements. However, more 
research is required to evaluate the relationship of home BP with other indices of TOD 
(Bliziotis et al., 2012). ABPM is therefore advisable under the following conditions: 
Suspected white coat hypertension; Suspected masked hypertension; Effect of identification 
white coat in hypertensive patients; Suspected irregular taking of antihypertensive; discard 
resistant hypertension (poor control of BP with antihypertensive); constant change BP during 
medical consultations; suspected postural hypotension, postprandial or drug induced; 
suspected pre-eclampsia in pregnancy and suspected nocturnal HTN (sleep apnoea and 
diabetes) [Mancia et al., 2013]. 
 
1.1.3.5. Laboratory tests 
Blood samples for assessment of HBP should preferably be taken with the patient fasting so 
that blood sugar level and more accurate lipid profiles can be obtained. Regarding 
electrolytes there is more attention on potassium and sodium; high levels of potassium can 
suggest renal disease, particularly if creatinine is elevated, and low values can suggest 
aldosterone excess. Increased serum creatinine and blood urea nitrogen (BUN) levels are 
generally indicative of renal damage; creatinine is also used in the formula for estimated 
glomerular filtration rate (eGFR). In the African setting, the formula designed for eGFR 
calculations should be used (National Kidney Foundation 2002).  
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The lipid profile is important in these patients since elevated low-density lipoprotein (LDL) 
cholesterol or low values of (HDL) high-density lipoprotein cholesterol are associated with 
increased cardiovascular risk (Mancia et al., 2013; Weber et al., 2014). Thus high LDL 
cholesterol should be treated with statins.  
Liver function tests to have baseline values of Aspartate aminotransferase (AST) and 
Alanine aminotransferase (ALT) are indicated because certain BP remedies can affect liver 
function (; Mancia et al., 2013; Weber et al., 2014).  
Fasting glucose concentration is also indicated because, if elevated could indicate impaired 
glucose tolerance, or, if high enough, could indicate DM (Chobanian et al., 2003; Mancia et 
al., 2013; Weber et al., 2014). 
A urine sample by dipstick urine is indicated especially when kidney disease is suspected. 
Albuminuria (30-300 mg/24h), proteinuria or albumin-creatinine ratio (30-300 mg/24h, 3.4 - 
34 mg/mmol) are important signs of CKD (Levey et al., 2005; National Kidney Foundation 
2002). 
In the African context with a high incidence of sickle cell anaemia associated with chronic 
kidney disease, haemoglobin/haematocrit can identify issues beyond HTN, which are 
important for management of HBP complications (Kider et al., 2011). 
 
1.1.3.6. Ultrasound of the carotid arteries 
Ultrasound-Doppler of the carotid arteries should be required in the following circumstances 
as suspicion of arterial thrombosis, narrowing of the arteries research (stenosis), post stroke, 
post transient ischemic attack, other causes of blockage in the carotid arteries, investigation 
of an abnormal sound (blow) on the carotid arteries in the neck and risk stratification and 
atherosclerosis research (Mancia et al., 2013). 
 
1.1.3.7. Magnetic Resonance 
The magnetic resonance (MRI) is indicated especially when suspected pheochromocytoma. 
It may also be useful in cases of suspicion of aortic coarctation, unspecific arteritis or HTN 
complications such as aneurysms. MRI should be considered to determine the size and 
mass of LV when echocardiography is technically not feasible and imaging of delayed 
enhancement would possibly imply therapeutic consequences (Codella et al., 2012; Parsai 





1.1.3.8. Renal ultrasound  
Renal ultrasound is indicated especially when there is suspicion of renal artery stenosis and 
acute or chronic renal failure (Mancia et al., 2013). 
 
1.1.4. Management of Hypertension 
The primary objective of treating HBP is the reduction of cardiovascular, renal, and ocular 
morbidity as well the mortality associated with these and other complications. For this, non-
pharmacologic measures are used in isolation or associated with the use of antihypertensive 
drugs. 
The target values for control of HBP are SBP below 140 and DBP below 90mmHg. 
Reductions below 130/80 mmHg are recommended for patients at high CV risk, especially 
with microalbuminuria, HF with renal impairment, those in secondary prevention of 
cerebrovascular disease and patients with type 2 DM (Ruilope et al., 2008; Mancia et al., 
2013; Weber et al., 2014). 
 
1.1.4.1. Nonpharmacological treatment 
Adopting a healthy lifestyle generally provides a significant drop in blood pressure, which 
may be enough to lower blood pressure to normal values. General measures to help reduce 
BP levels include salt restriction and its derivatives (broth, soy sauce), adequate 
consumption of vegetables and fruits and low-fat produce, moderate alcohol consumption, 
weight reduction, regular physical activity and to quit smoking. Lifestyle changes for up to 6-
12 months can be attempted in the hopes that they may be sufficiently effective in discarding 
the use of anti-hypertensive drugs (Mancia et al., 2013; Weber et al., 2014; Chobanian et al., 
2003). 
 
1.1.4.2. Pharmacological treatment 
The primary objective of pharmacological treatment is to reduce BP levels and, through BP 
control, prevent fatal and non-fatal cardiovascular events. Appropriate combinations of 
antihypertensive medications should be used. The socio-economic condition of the patient 
(for example age, ethnicity/race and other conditions as diabetes and coronary disease and 
pregnancy in women) at the time of prescription medication should always be considered. 
Usually, a minimum period of 2 – 3 weeks is needed for dosage increase, replacing 
monotherapy or changing the drug association. Special consideration should be made in 
situations where there are concomitant risk factors; for instance, Angiotensin Converting 
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Enzyme inhibitors (ACE) must be used primarily in patients with DM (Weber et al., 2014; 
Mancia et al., 2013). 
 
 
1.1.4.2.1. Low dose diuretics 
Diuretics are the most studied drugs that have proven beneficial in reducing cardiovascular, 
cerebrovascular and renal events. They are low-cost drugs, have been used for a long time 
and are recommended as a first antihypertensive option for "monotherapy", especially for 
patients with HTN stage 1, who did not respond to non-drug measures. These agents 
increase the excretion of sodium by the kidneys and may also have some vasodilator 
properties. Their main side effects are metabolic namely hypokalemia, hyperglycaemia and 
hyperuricemia. Thiazides plus beta-blockers are an effective combination to reduce BP 
levels; however, both classes can increase blood sugar concentrations this combination 
should be used cautiously in patients at risk for developing DM (Weber et al., 2014; 
Chobanian et al., 2003).  
The thiazides diuretics are favourable indicated in elderly patients, systolic HTN and post-
stroke. Loop diuretics such as furosemide should be used in HTN associated with kidney 
disease and HF. The thiazide-like diuretics such as chlorthalidone and indapamide show to 
be more effective than thiazides (Mancia et al., 2013; Chobanian et al., 2003). 
 
1.1.4.2.2. Calcium channel blockers 
These agents decrease the BP levels through the blockage of the inward flow of calcium 
ions through the L channels of arterial smooth muscle cells. The main types of calcium 
channel blockers are: (1) dihydropyridines, such as amlodipine and nifedipine, which work by 
increasing the surface area of the arteries; and (2) non- dihydropyridines, such as diltiazem 
and verapamil, which dilate arteries somewhat less, but also lower the heart rate (HR) and 
contractility (Weber et al., 2014). 
The favourable indications for calcium channel blockers are elderly patients, angina pectoris 
and systolic HTN. Calcium channel blockers have potent effects of BP reduction, particularly 
when combined with ACE inhibitors or angiotensin receptor blockers. The effects of this 
class of anti-hypertensive drugs are similar in all racial and ethnic groups (Weber et al., 
2014). In some context, calcium channel blockers are considered the first-line treatment of 
HTN in black patients (instead of ARBs or ACEi). 
The most common side effect of these agents is peripheral oedema, which increases with 
high doses (this can be attenuated by combining these agents with ACE inhibitors or 
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angiotensin receptor blockers). Nondihydropyridine calcium channel blockers are not 
recommended in patients with HF, but amlodipine appears to be safe when given to HF 
receiving ACE inhibitors for this condition (Weber et al., 2014; El-Deeb et al., 2015). 
 
1.1.4.2.3. Adrenergic antagonists 
The adrenergic antagonists can be beta-blockers or alpha-blockers.  
Favourable indications for beta-blockers are previous infarction, angina pectoris, 
tachycardia, arrhythmias, diastolic dysfunction and after control of congestive HF in those 
with severe myocardial dysfunction. Propranolol is still used in patients with hemodynamic 
instability for its short duration of action, and because there is a low prevalence of peripheral 
arterial disease. The common side effects of this class of antihypertensive agents include 
reduction of the sexual function, hyperglycaemia, fatigue and reduction of the tolerance in 
the physical activity.  
Alpha-blockers are less used but preferred in patients with benign prostate hyperplasia. 
They can also be used in treating resistant HTN when combined with diuretics, beta-blockers 
and ACE inhibitors (Weber et al., 2014; Chobanian et al., 2003). 
 
1.1.4.2.4. Angiotensin-converting enzyme inhibitors 
Angiotensin-converting enzyme (ACE) inhibitors agents decrease blood pressure through 
the blockage of the renin-angiotensin system, and they are well tolerated. The most widely 
used are captopril, enalapril, perindopril and lisinopril.  
The favourable indications of ACE are HF, LV systolic dysfunction, post-myocardial 
infarction, diabetic and nondiabetic with chronic kidney disease, post-stroke, and proteinuria. 
The most frequent side effects are a cough (most common in women and in patients of 
African and Asian background) and angioedema (uncommon and severe complication). The 
side effects associated with ACE inhibitors are generally not dose-dependent, as they may 
happen at low doses or at high doses (Weber et al., 2014; Chobanian et al., 2003). 
 
1.1.4.2.5. Angiotensin II receptor antagonists 
Angiotensin II receptor antagonists (ARA), like angiotensin-converting enzyme inhibitors, 
antagonise the renin-angiotensin system (Weber et al., 2014). Drugs in this class include 
Irbesartan, olmesartan, valsartan, losartan, candesartan and azilsartan medoxomil are 
available. The most commonly used in Mozambique are losartan, valsartan and irbesartan, 
sometimes in association with hydrochlorothiazide. They are chosen for treatment of HTN, 
especially when associated with conditions such as HF or kidney disease in people with 
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diabetes. On the other hand, angiotensin II receptor blockers compared to the ACE inhibitors 
are well tolerated and often do not cause a cough and rarely cause serious complications 
such as angioedema (Weber et al., 2014; Mancia et al., 2013; Chobanian et al., 2003). 
 
1.1.4.2.6. Centrally Acting Agents 
The most commonly known are methyldopa and clonidine, with methyldopa being the most 
frequently used in our setting. The main effect of these agents is to reduce the sympathetic 
outflow from the central nervous system. They are effective in reduction of BP levels in 
patients with severe HTN and pregnancy. Their main side effects are drowsiness and dry 
mouth (Weber et al., 2014; Chobanian et al., 2003). 
 
1.1.4.2.7. Mineralocorticoid Receptor Antagonists 
The best known agent of this class is spironolactone, which has recently become part of 
standard treatment for HF. Eplerenone is a newer and well-tolerated agent. In resistant HTN, 
for patients not controlled on 3 agents, adding spironolactone will often be helpful. The 
symptomatic side effects are gynecomastia, sexual dysfunction and hyperkalaemia (Weber 
et al., 2014; Chobanian et al., 2003). 
 
 
1.1.4.2.8. Recommended Hypertensive Medication in Mozambique 
According to the National Strategic Plan for the Prevention and Control of NCDs at Ministry 
of Health (MOH), Mozambique is using four lines to HBP treatment (Damasceno, 2011). 
First-line agents: The most commonly used in Mozambique is the thiazide diuretic as 
hydrochlorothiazide (HCTZ), associated with a potassium-sparing (amiloride) agent to 
prevent hypokalaemia. It is extraordinarily cheap, taken only once a day and incidence of 
hypokalaemia is reduced. However, in pregnancy, renal failure, or diabetes, a different 
medication should be used first. 
Second-line agents: Of the drugs belonging to this group the most widely used in 
Mozambique are amlodipine and nifedipine, which have been demonstrated as having 
positive effects on CV and stroke outcomes in hypertension trials. Patients having moderate 
or severe HTN (stage 2 and 3) will likely need at least two drugs to achieve BP control. In 
such circumstances, at baseline, patients need to begin at the starting dose of both the first- 
and second-line agents. 
Third-line agents: In many patients with stage 3 hypertension two drugs, even taken at high 
doses, may not be sufficient in controlling the BP levels. ACE inhibitors are the preferred 
third-line after the maximum dose of HCTZ and amlodipine have been reached. The most 
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widely used are enalapril and captopril. ACE inhibitors are contraindicated in pregnancy and 
renal failure (creatinine ≥ 200 umol/L). 
Fourth-line agents: In some cases, patients may have high blood pressure that is resistant 
to antihypertension drugs. Four medications for BP control may be required. Of this group, 
the most commonly available in our setting are beta-blockers such as propranolol, atenolol, 
carvedilol, metoprolol and bisoprolol. Atenolol is the fourth-line antihypertensive 
recommended due to its availability and accessibility. 
 
1.1.4.3. Special considerations 
 
1.1.4.3.1. HBP in Pregnancy 
Hypertensive disorders (preeclampsia, eclampsia gestational hypertension, and chronic 
hypertension with superimposed preeclampsia) are common complications of pregnancy, 
and it occurs in 6-8% of pregnancies and complicates about 5% to 10% of all pregnancies 
(Report of the National High Blood Pressure Education Program in Pregnancy, 2000). On 
the other hand, pregnancy may aggravate existing HTN before pregnancy (chronic HTN) 
and induce it in normotensive women (gestational HTN and preeclampsia).  
HTN is the most common medical complication of pregnancy and a major cause of maternal 
mortality as well as perinatal morbidity and mortality worldwide (Berg et al., 2010; Sliwa et 
al., 2014). In Africa, hypertensive related conditions account for about 9% of overall maternal 
deaths (Khan et al., 2006).  
In pregnancy, the main objectives of antihypertensive treatment are to protect the mother 
from acute risks or irreversible damage during or immediately after pregnancy and to allow 
the delivery of a full-term healthy new-born. In a normal pregnancy, BP tends to fall. Blood 
pressure > 140 mmHg systolic or > 90 mmHg diastolic is considered elevated. Blood 
pressure > 160 mmHg systolic or > 100 mmHg diastolic is considered severely high (Martin 
et al., 2005).  
The management of HTN in pregnancy is complicated by the fact many common 
antihypertensive drugs cause birth defects. However, few clinical trials have investigated the 
treatment of HTN in pregnancy, and therefore there is significant disagreement on the 
subject. Considering the potential risks of antihypertensive therapy during pregnancy - drugs 
can reduce uteroplacental flow and compromise the fetus - treatment of diastolic blood 
pressure below 100 or 110 mmHg is usually avoided. When the diastolic blood pressure 
levels exceed 100 mmHg, treatment should be instituted to prevent maternal vascular injury. 
Medical therapy of severe HTN in pregnant women (> 160 for SBP or > 110 for DBP) is 
therefore highly recommended and beneficial (Abalos et al., 2001). However, excessive 
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blood pressure reduction should be avoided, considering the risk of hypo perfusion of 
maternal and fetal compromise target organs by uteroplacental ischemia when 25% drop 
from the initial value is done.  
To date, there is insufficient evidence to know what is the best drug therapy to use when 
starting treatment, how intense it should be and when it should be stopped. There is no 
scientific evidence that treatment with antihypertensive drugs in mild to moderate HTN (≤ 
160/110 mmHg), improve perinatal outcome, e.g., decrease the incidence of complications, 
such as intrauterine growth restriction (IUGR), pre-eclampsia overlay, detachment premature 
placenta or perinatal mortality (Abalos et al., 2001). 
Recommended hypertensive agents include methyldopa, nifedipine, atenolol and 
hydralazine. Beta-blockers (propranolol) and thiazide diuretics have relative 
contraindications. ACE inhibitors and ARA are absolutely contraindicated due to undesirable 
side effects, both to the mother and the fetus (Mancia et al., 2013).  
  
1.1.4.3.2. Management of Hypertension Emergency in Adults 
Critical increase in the blood pressure levels can result in TOD in a matter of hours. These 
hypertensive emergencies frequently happened when the BP is > 180 mmHg systolic or > 
110 mmHg diastolic. Signs of a HTN emergency are: headaches and blurred vision caused 
by increased intracranial pressure, dyspnoea caused by an acute stiffening of heart and 
back-up of fluid into the lungs, and haematuria or flank pain caused by damage in the 
kidneys. Patients who present with these symptoms related to HTN and a BP level of 
180/110 mmHg or greater should be treated vigorously (nifedipine or captopril or hydralazine 
or furosemide) to lower their BP by approximately 25% in the first hour (Damasceno, 2011; 
Kider et al., 2011). 
 
1.2. Justification 
HTN is one of the most frequent reasons of heart failure in the world, particularly in the 
African context, and most patients who develop HF have a background of HTN 
(Papademetriou, 2004; Dokainish et al., 2016; Dokainish et al., 2015). In the Global Burden 
of Disease 2010 Project (Murray et al., 2012), hypertensive heart disease which comprises 
HTN, HTN with LVH and hypertensive heart failure (Ojji et al., 2015) was one of the top 
causes of disability-adjusted life years (DALYs). In Africa, HTN is a major risk factor for CV 
events (Stewart et al., 2008; Ojji et al., 2009; Damasceno et al., 2012; Ojii et al., 2013) and a 
leading cause of cerebrovascular accident, chronic kidney disease and HF (Minino et al., 
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2011). A registry of 1006 consecutive patients with acute HF, predominantly black patients 
from 9 African countries including Mozambique, revealed HBP as the most common cause 
of acute heart failure (453, 45.4%) [Damasceno et al., 2012]. Several other studies 
corroborate these findings: HTN is a prominent cause of HF in Nigerians account for 
approximately 60% of the cases (Ojji et al., 2009; Onwuchekwa et al., 2009; Ojji et al., 2013; 
Ojji Ojji et al., 2015); in Cameroon, accounting for about 54% of all heart failure cases 
(Kinque et al., 2005) and in South Africa it was responsible for 33% of HF in the Heart of 
Soweto study (Stewart et al., 2008). In Abuja Heart Study (Ojji et al., 2013), a cohort of 1,515 
subjects attending a cardiac clinic in a tertiary set up, hypertensive heart failure (HHF) was 
the primary type of heart failure in 60% of the cases and accounted for 33% of the total 
cohort. 
Early asymptomatic changes such as LVH, proteinuria and renal failure, heart attacks, 
stroke, retinopathy and vascular dementia occur (Nadar et al., 2006), but due to its silent 
nature hypertension is frequently associated with sudden death. Recent studies on 
hypertensive TOD report that hypertensive heart disease, hypertensive nephropathy, 
hypertensive retinopathy, stroke, and ischaemic heart disease are frequent, even at the first 
contact in healthcare facilities in African settings (Peer et al., 2008; Ekore et al., 2009; 
Stewart et al., 2009; Oladapo et al., 2012). By the time of diagnosis, most patients would 
have developed TOD and ACC due to low levels of detection, adequate treatment, 
management and control. Moreover, in some SSA countries including Mozambique, HTN is 
the main reason for seeking health care services in the adult population (Ogah, 2006; 
Damasceno et al., 2011).  
The risk of developing TOD in some African populations is higher in patients with severe 
HTN; 3.61 (0.59-8.73) for those with recently diagnosed HTN compared to 4.76 (1.30-13.06) 
for those with BP equal or greater than 180/110 mmHg. (Oladapo et al., 2012) In Nigeria 
TOD prevalence in hypertensives was twice as high as that found in non-hypertensive adults 
(32% and 15%, respectively), and severity of HTN was a strong determinant for target-organ 
damage [grade 1 odds ratio 2.66, 95% confidence interval (CI) 1.04-6.84; grade 2 OR 3.82, 
95% CI 1.41-10.36] (Nelissen et al., 2014). In the Sub-Saharan Africa Survey of Heart 
Failure Study (THESUS), 289 patients (30.6%) had glomerular filtration rate ≤ 60ml/min 
(Damasceno et al., 2012). Renal dysfunction during hospitalisation was detected in 53 
(9.8%) of 543 patients with follow-up creatinine values. Renal dysfunction was also prevalent 
in young patients without acute non-ischemic HF in Africa, but severe renal dysfunction was 
less prevalent and was one of the different predictors compared to Western Cohorts (Sani et 
al., 2014). 
Finally, a study conducted in the capital city of Mozambique showed a yearly incidence of 
stroke of 148.7 per 100,000 populations and 260.1 per 100,000 in the population aged over 
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25 years (Damasceno et al., 2010), much higher than 123.9 per 100,000 found in the United 
Kingdom (Wolfe et al., 2000). HTN was the most important risk factor in these patients and 
determined high mortality rate (in-hospital mortality: 33.3%, 28 days of mortality: 49.6%), 
especially through haemorrhagic stroke associated with HTN (Damasceno et al., 2010). 
LVH, defined as left ventricular wall thickness and/or mass, is the best-studied marker of 
hypertensive heart disease (Mensah GA et al., 1994). It is an independent CV risk factor, 
and as potent as systolic blood pressure or age in predicting a cerebrovascular accident, 
myocardial infarction, sudden death or HF (Kannel et al., 2003). 
Chronic systolic HTN demonstrates to be the main cause of left ventricular hypertrophy 
(Levy et al., 1988; Rheeder et al., 1999), which serves as an integrated surrogate for 
cumulated blood pressure load, and correlates well with mean 24-hour ambulatory blood 
pressure (Wendelin–Saarehovi et al., 2002; Mancia et al., 1997). Although healthy young 
blacks are known to have greater left ventricular wall thickness compared to white population 
(Aje et al., 2009; Hinderliter et al., 1992), hypertensive LVH is more prevalent in African-
Americans (Post et al., 2003, Houghton et al., 1997; Chaturvedi et al., 1994; Gott diener et 
al., 1994; Gardin et al., 1995; Koren et al., 1993), highlighting the need for studies in the 
African population. 
With the high prevalence of HTN at 33.1% and low rates of treatment and control 
(Damasceno et al., 2009), Mozambique is expected to have a high occurrence of HHF. The 
mechanisms that determine HHF are still quite contested, but they would involve a stepwise 
progression from HTN to left ventricular hypertrophy, then to heart failure with preserved 
systolic function and eventually to ventricular dilatation and cardiac failure (Izzo and 
Grandman, 2004). The possible pathways include: (1) progression of HTN to concentric left 
ventricular hypertrophy, (2) progression of HTN directly to hypertensive heart with dilated left 
ventricle and reduced left ventricular systolic function with or without myocardial infarction, 
(3) progression of HTN through concentric hypertrophy to HF with or without transient 
myocardial infarction with reduced left ventricular systolic function, and (4) progression of 
HTN through concentric hypertrophy to HF with preserved ejection fraction (Drazner, 2005). 
In hypertensive subjects in SSA with a relatively low prevalence of coronary artery disease, 
the progression of HTN either directly to HF or through concentric left ventricular hypertrophy 
without transient myocardial infarction are favoured. Similarly, the mechanisms that lead to 
ventricular dilatation in patients with decompensating left ventricular hypertrophy are not 
completely comprehended (Slama et al., 2003). It is implicated that in patients with systolic 
dysfunction, activation of the sympathetic nervous and renin-angiotensin-aldosterone 
systems causes, (1) vasoconstriction, (2) salt and water retention and (3) progressive 
ventricular dilatation and remodelling. All the above-mentioned processes constitute 
maladaptation events which create a vicious cycle that gradually aggravates cardiac 
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performance (Williams, 1999). As the cardiac function slowly declines, there is no additional 
increase in left ventricular mass due to apoptosis (Sun et al., 2001).  
In the myocardium, the modification of the gene expression pattern that accompanies the 
transition from left ventricular hypertrophy to heart failure includes a general decline in 
contractile proteins. Simultaneously, interstitial protein synthesis continues leading to 
myocardial stiffness, impaired diastolic relaxation and the reduction in the vigour of the 
physical activity tolerance (Rerkpattanapipat et al., 2002). Ultimately, there is reduced 
myofibrillar activity, ventricular dilatation and heart failure (Weber et al., 2001). In addition, 
concomitant large and small blood vessel changes intensify the progression from left 
ventricular hypertrophy to heart failure. The aorta gets hardened with impairment of 
ventricular vascular coupling and increased cardiac afterload (Chae et al., 1999). Coronary 
flow reserve is also reduced by left ventricular hypertrophy and is eroded further by 
progressive ventricular dilatation (Cowie et al., 2002). Follow up of patients with severe HTN, 
such as the one proposed in our study, may help understand the natural history of HHF.  
Echocardiography, an important tool for evaluation of severe and complicated HTN, is 
currently done by specialists. It evaluates the geometric pattern of the LV, estimates cardiac 
output, systolic function, and coexistence of other cardiac diseases (such valvular or 
coronary). It is also helpful in quantifying the ejection fraction (EF) in patients when we 
suspect HF (Weber et al., 2014), although this complementary exam is not routine in 
patients with hypertension. EF is a quantification of the heart´s systolic function and is used 
to distinguish patients with HF with depressed or preserved EF). EF is commonly classified 
as normal (≥ 55%), mildly reduced (40%-55%), and moderately to severely reduced (< 40%). 
A moderately to severely reduced ejection fraction implies a patient has a cardiomyopathy. 
While echocardiography machines generate measurements of EF, qualitative visual 
assessment is also very consistent and may be through to non–cardiologists (Lebeau et al., 
2015).  LVH regression with antihypertensive treatment, which also improves LV filling and 
performance, and consequently decreases morbidity and mortality from cardiac and 
cerebrovascular events, can also be assessed by ultrasound. The dissemination of 
ultrasound machines offers an opportunity for better management of patients with severe 
HBP and HHF at peripheral levels of the health system. Focused or abbreviated 
echocardiography performance by non-specialists has been introduced in some African 
countries as a way to improve access to better care for patients with HHF (Kider et al., 2011; 
Lebeau et al., 2015). 
Mozambique has a high prevalence of HIV/AIDS 13.2% (IMASIDA Report, 2015) and thus 
concomitant HHF and HIV infection are not rare. Because HIV infection has also been 
associated with severe systolic dysfunction there is need to understand the role of this 
infectious agent in determining HHF. Two recent studies have observed at the impact of HIV 
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status on the prevalence of HTN in SSA at the community level. In 2003–2004, 
Barnighausen and his co-workers studied the effect of HIV on body mass and BP in a large 
general population in a rural area in South Africa before antiretroviral treatment (ART) 
became widely available (Geldsetzer et al., 2016). After controlling for confounders such as 
age, gender, educational attainment, household wealth, marital status, and place of 
residence (urban vs. rural), HIV infection reduced SBP by 3.0 mm Hg (p=0.005). According 
to the authors, it was suggested that the possible reason for the results obtained may have 
been influenced by HIV-related hypoadrenalism and/or side effects of traditional medicines 
against HIV/AIDS. Malaza et al. (2012) published the results of a survey conducted in 2010 
based on the WHO Stepwise approach in 14,198 adult participants living in rural areas in 
South Africa to determine factors associated with HTN and overweight/obesity, including HIV 
infection and ART status. They concluded that the prevalence of HTN differed between HIV 
positive and HIV negative individuals (19.5% vs 27.9%, p=0.001). HIV-uninfected women 
were significantly more likely to be hypertensive than HIV-infected women (31.4% vs 20.1%, 
p=0.001), while there was no association of HTN with HIV status among men (p=0.099). 
HIV-positive individuals on ART treatment had a reduced adjusted odds ratio (OR) of HTN 
(OR 0.60, 95% CI 0.49 to 0.75), compared to HIV-negative individuals, but the adjusted OR 
in HIV-positive individuals not on ART did not differ from HIV-negative individuals (p=0. 
0.158). With the advent of highly active ART, long-term survival of HIV-positive individuals is 
expected and this will be associated with cardiovascular and metabolic complications.  
In summary, much of Africa has a limited capacity in the health care system to screen, 
diagnose, treat and control systematic HTN and their RF and complications (Campbell et al., 
2015). On the other hand, low literacy rates, poor access to healthcare services, inadequate 
dietary habits, scarcity of health insurance systems, poverty and high costs of 
antihypertensive treatment, all contribute to poor BP control (Ibrahim and Damasceno, 2012; 
Campbell et al., 2015). This situation predisposes to TOD and serious cardiovascular events 
such as stroke and HF (Salako et al., 2007; Campbell et al., 2015).  
Given the high incidence and prevalence of severe HTN in Mozambique and the lack of 
statistical data on its complications and clinical outcomes our study aims at characterising 
severe and complicated HTN assisted at a peripheral health facility with the use of 
biomarkers and abbreviated cardiac ultrasound, as well as follow-up these patients to 
assess outcomes in an environment with limited resources. The results of this study are 
expected to contribute to a better knowledge of the disease and allow the design of protocols 
for management of severe HTN and early detection of its complications at peripheral levels 





CHAPTER 2: HYPOTHESES, AIMS AND OBJECTIVES 
 
2.1. Hypotheses 
Hypothesis 1: Patients with severe hypertension with at least two drugs have a unique 
clinical and biological profile, with high occurrence of TOD/ACC; 
Hypothesis 2: Patients with severe and complicated hypertension can be characterized and 
managed by non-specialists, through the use of simplified diagnostic and management 
protocols including the use of biomarkers and abbreviated cardiac ultrasound. 
 
2.2. Aims and Objectives 
The general aim of the study is to characterise severe and complicated hypertension and 
determine the frequency of associated TOD and ACC in patients attending in a referral 
hospital in Maputo. 
 
The specific objectives of the study were:  
a) To characterise the clinical profile of patients with severe HTN using biomarkers, 
funduscopic and focused/abbreviated echocardiography; 
b) To determine the incidence of severe cardiovascular events (HHF, stroke), renal 

















3.1.1. Study Area  
The Mavalane General Hospital (HGM) is located in Maputo City and serves a population of 
670,877 habitants, over an area of 168.4 km2. This hospital has 260 beds and assists on 
average 700 patients daily in the outpatient clinic and emergency department. It is the 
referral hospital for 14 primary health centres and has several specialised services for 
Paediatrics, Internal Medicine, Psychiatry, Psychology, Cardiology, Gynaecology/Obstetrics, 
General Surgery, Dentistry, Ophthalmology and Anaesthesiology. (Relatório Anual do 
Hospital Geral de Mavalane, 2015). Support services include Laboratory of Clinical Analysis, 
Radiology, Blood Bank, Pharmacy, Emergency Service, Operating Blocks and 
Physiotherapy. The Cardiology Unit has only one cardiologist, four general practitioners and 
two trained nurses that have been trained for follow-up common conditions seen in our 
setting. 
 
3.1.2. Study Population 
Patients were referred from outpatient’s clinic and wards of Internal Medicine, Surgery, 
Anaesthesiology, Gynaecology/Obstetrics, Ophthalmology, and emergency unit of HGM. We 
also received direct referrals from Mavalane Primary Health Care (physically attached to the 
Hospital) and.  
Since there are no data on the percentage of patients with severe HTN in similar populations 
or the proportion of those who develop complications, the sample size was not calculated. 
We have decided to recruit at least 100 adult patients with a diagnosis of severe or 
complicated HTN during the 12 months. 
 
3.1.3. Study Design 
We designed a prospective descriptive cohort study, to assess patients with severe and 
complicated hypertension presenting to the Cardiology Department at Mavalane Hospital in 
Maputo. The study was conducted from July 2015 to May 2017. 
a. Inclusion criteria: 
 Adults ≥ 18 years; and 
 HTN grade 3 (BP ≥180 / 110 mmHg or BP ≥160 / 100 mmHg with presence of 1 or 2 
RF) with or without antihypertensive drug or HTN (BP ≥140 / 90 mmHg) with 
presence of target organ damage; and 
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 Residence in Maputo Province (within 100Km surrounding area); and 
 Availability for follow-up for a period of 6 months. 
 
b. Exclusion criteria: Presence of severe disease or psychiatric disorder not allowing 
the obtainment of informed consent.  
 
3.1.4. Study Procedures  
All participants provided a signed informed consent to participate in the study. 
All participants had their blood collected to test for the following: fasting blood sugar (FBS), 
fasting lipid profile, electrolytes, urea, creatinine, aspartate aminotransferase, alanine 
aminotransferase and full blood count assessed. Blood chemical analysis was performed at 
the certified laboratory. They also had an abbreviated transthoracic echocardiography 
performed the same day that the samples were collected for routine analyses. 
We scheduled 5 visits in a period of 6 months during which follow up was performed: Visit 1 
– Baseline; Visit 2 - 1 week after V1; Visit 3 - 2 weeks after V2; Visit 4 - 4 weeks after V3; 
Visit 5 - 8 weeks after V4; and Visit 6 - 4 weeks after V5. 
 
The candidate constituted a study team that consisted of:  
 General Physician (candidate): Recruited and evaluated the participants in study 
(including verification of the informed consent), namely collected socio-demographic 
information, personal and family history; performed physical examination; requested 
laboratory tests and other complementary tests; prescribed therapy according to local 
protocols (Damasceno, 2011) and did the follow-up visits.  Additionally, entered data 
and performed statistical analysis. 
 Nurses: Hospital nurses invited the eligible participants to participate in the study, 
administered the informed consent, collected the vital signs and anthropometric data 
(BP, heart rate, height, weight, waist circumference and bio impedance analysis) and 
did the electrocardiogram in all patients.  
 Laboratory Technician: collected blood samples, transferred them to the laboratory, 
and processed the samples and collected the results. 
 Ophthalmologist: performed all funduscopic examinations. 
 Cardiologist (supervisor AOM): assisted with clinical evaluation when needed; 
performed and interpreted abbreviated echocardiography. 
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 Data management was supported by members of the supervisor’s team. 
 
3.1.4.1. Description of Procedures 
 
3.1.4.1.1. Questionnaire 
A standard case report form (CRF) was used to collect baseline and follow up data from 
each participant. Due to the multiplicity of languages in Mozambique, the Portuguese 
questionnaire was not translated into any local languages; the majority of the participants 
were reasonably proficient in the Portuguese and, where there was a need for translation, 
both medical and para-medical staff (nurse) assisted the participant.  
Detailed socio-demographic data was collected including date of birth, gender, race, 
occupation, school level and marital status. The structured questionnaire also included past 
personal medical history (previous diagnose of HTN, diabetes mellitus, cerebrovascular 
disease, HF and myocardial infarction), the pattern of physical activity, drinking (alcohol) and 
smoking habits (self-reported). Family history of HTN, DM, stroke and myocardial infarction 
was also requested. Use of anti-hypertensive medication or any other drugs (self-reported) 
were registered. 
Regarding the level of education obtained, participants were classified as ‘‘Primary’’ when 
they had completed 7 years of education or less, ‘‘Secondary’’ when they had completed 
secondary school, meaning in total 12 years of education; and, finally, ‘‘Tertiary’’ when they 
had obtained a university or professional degree. 
 
3.1.4.1.2. Clinical Evaluation 
 
3.1.4.1.2.1. Anthropometric Measurements 
Anthropometric measurements (weight, height and waist circumference) were performed 
using standardized methods. Height was measured to the nearest 0.1 cm using a portable 
Seca stadiometer. Weight was measured to the nearest 0.1 kg using a calibrated Seca 
weight scale.  
Body Mass Index (BMI) was calculated as weight in kilograms divided by height in meters 
squared [weight (kg)/height (m2)]. BMI was categorized as per the World Health 
Organization guidelines (WHO, 1996), underweight (BMI < 18.5), normal (BMI ≥18.5 to ≤ 
24.9), overweight (BMI ≥ 25.0 to ≤ 29.9) or obese (BMI ≥ 30.0). Waist circumference was 
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used as a measure of abdominal obesity; it was measured to the nearest 0.1 cm, using a 
constant tension tape, directly over the skin, at the level of the midpoint between the inferior 
margin of the last rib and the iliac crest in the midaxillary line in all patients. For analysis, the 
cut-offs used were waist-circumference ≥102 cm in men and ≥88 cm in women (WHO, 1997; 
WHO, 2008: WHO, 2011).  
All measurements were performed with the participant dressed in light clothing and without 
shoes. 
 
3.1.4.1.2.2. Bio impedance analysis 
Bio impedance analysis (BIA), a non-invasive and low-cost technique commonly used to 
assess body composition, was done in all patients, except for those patients who are in the 
wheelchairs. BMI, body fat muscle, RM kcal and visceral fat were measured with the 
participants standing, wearing indoor clothes with no shoes. 
 
3.1.4.1.2.3. Conventional Blood Pressure Measurements 
 
Hypertension was defined according to the JNC VII guidelines (Chobanian et al., 2003; 
JNC7 Report, 2004) and WHO-ISH, 1999. Blood pressure measurements were obtained by 
trained health workers (nurses and the candidate) according to International Society of 
Hypertension guidelines. (WHO-ISH, 1999; Chobanian et al., 2003; American Society of 
Hypertension, 1992), A validated automatic sphygmomanometer was used (OMRON M2 
Plus; OMRON Healthcare, Kyoto, Japan) and the appropriately sized cuff was chosen for 
each patient. SBP and DBP were measured in both arms with the patient in a sitting position. 
After 5 minutes rest, SBP and DBP were measured again in both arms. For analysis we took 
the mean of the 2 measurements from the right arm. 
Mild HTN (grade 1) was defined by values between 140-159 mmHg SBP and 90-99 mmHg 
DBP; Moderate HTN (grade 2) was defined by values between 160-179 mmHg SBP and 
100-109 mmHg DBP; and Severe HTN (grade 3) was defined as SBP values ≥ 180 mmHg 
and/or DBP ≥ 110 mmHg; or SBP ≥ 160 mmHg and SBP values ≥ 100 mmHg in the 
presence of 1 or 2 RF or TOD (Chobanian et al., 2003) with or without antihypertensive 
treatment . 
Complicated hypertension was defined by values above 140 mmHg for SBP and/or 90 
mmHg for DBP, in the presence of impairment in the function of a target organ such as the 
brain, arteries, heart, eyes and kidneys. Isolated systolic hypertension was characterized 
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by SBP ≥ 140 mmHg and DBP < 90 mmHg (often with normal DBP). Controlled BP was 
defined as treated HTN with SBP < 140 mmHg and DBP < 90 mmHg in respondents using 
antihypertensive medication. The average on the follow-up visits was used as a criterion for 
the diagnosis of controlled HTN. 
 
3.1.4.1.2.4. Physical Examination 
On physical examination, the vital signs were assessed and evaluation of all palpable arterial 
pulses in the arms and limbs on both sides was made to discard aortic coarctation and 
Takayasu. Cardiovascular and abdominal examination included auscultation of precordial or 
chest murmurs (to discard aortic disease); systolic murmurs in carotid arteries (to discard 
atheroma plaques); search for 4th heart sound, arrhythmias, pulmonary rales, as well as 
murmurs on the abdomen to discard stenosis of the renal artery. Additionally, we searched 
signs of HF such as increased pressure/distended jugular veins (PJV), 3rd heart sound, 
congestive hepatomegaly and peripheral oedema. 
Heart failure and HHF were diagnosed following the European Society of Cardiology 
guidelines (Swedberg et al., 2005; Nieminen et al., 2005). Stroke was defined as “a focal (or 
at times global) neurological impairment of sudden onset, lasting more than 24 hours (or 
leading to death), and of presumed vascular origin”, as per World Health Organization 
clinical definition (Hatano, 1976); it was identified through the history of a previous event 
(including transient ischaemic stroke) and a focused neurological examination looking for 
motor or sensorial defects. 
An experienced ophthalmologist who was blinded to the blood pressure levels of the 
subjects carried out the funduscopic retinal examination. As this exam is not done routinely 
at this level of healthcare, we negotiated for a joint appointment with the ophthalmologist 
once a week. Even before the researchers have the result of the funduscopic (by the waiting 
time for the participant to take the exam and have its result), we would decide to start more 
intensive antihypertensive therapy to achieve BP control < 140/90 mmHg. Hypertensive eye 
damage was diagnosed based on the Keith-Wagner-Barker criteria for hypertensive 
retinopathy, through which patients are divided into 4 grades (Keith et al., 1974).  
3.1.4.1.2.5. Complementary Exams 
a) Blood Measurements 
Venous blood samples were obtained via the ante-cubital vein for biochemical assessment, 
including the levels of fasting blood sugar, lipids (cholesterol and triglycerides), urea, 
creatinine, AST, ALT, uric acid, iron, gamma-glutamyl transferase (GGT), albumin and full 
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blood count. The samples were processed at the central certified laboratory of Mavalane 
Hospital using Pentra ABX 400/Beckman Coulter 640 and Sysmex KX-21N machines. 
Hyperglycaemia was defined as fasting plasma glucose 5.6 – 6.9 mmol/L and diabetes 
mellitus (new-diagnosed) as fasting plasma glucose of 7.1mmol/L or above (Mancia et al., 
2013). 
Hypercholesterolemia was defined as total cholesterol greater than 4.9mmol, 
hypertriglyceridemia as TG greater than 1.7 mmol/L (Mancia et al., 2013), and 
dyslipidaemia was defined as total cholesterol ratio more than 5.2 mmol/L or recorded 
physician diagnosis or treatment with lipid-lowering drugs (Ojji et al., 2013; Redon et al., 
2016).  
Anaemia was defined as haemoglobin levels below 12gr/dl for non-pregnant women and 
13gr/dl for men in 15 years of age and above. And, severe anaemia was defined as 
haemoglobin levels below 8 gr/dl in 15 years of age and above (WHO, 2011). 
CKD was defined by a confirmed positive dipstick proteinuria or albuminuria (at least traces) 
and/or or eGFR < 90mL/min/1.73m2. The Kidney Disease improving global Outcomes 
(K/DIGO) guidelines were used to stage participants for GFR categories and albuminuria 
categories of CKD (K/DIGO guidelines, 2013).  The eGFR categories included: G1 (eGFR ≥ 
90), G2 (eGFR 60-89), G3 (eGFR 30-59), G4 (eGFR 15-29), and G5 (eGFR < 15). The GFR 
(assessed by creatinine clearance) was calculated using the CKD-EPI Creatinine 2009 
Equation (Schwartz et al., 2009). Impaired eGFR was defined as an eGFR < 
60mL/min/1.73m2.  
HIV tests were done using the Determine HIV test; if the result was positive an Unigold HIV 
test was used to confirm the results (as per standard at National Health Service). In HIV-
positive participants, we assessed CD4 cells count using the FacsCalibur machine. 
 
b) Urine test 
A mid-stream clean-catch urine sample was collected from each patient in a sterile universal 
bottle for urine microscopy. The urine dipstick tests for albuminuria were done on the first 
urine sample and were processed in central laboratory of Mavalane Hospital or at our 
consultation when the laboratory could not perform it (as a point-of-care test using urine 
dipstick). The dipstick tests were done using the Urine Insta Test (urine reagent strips). 
The albuminuria categories of CKD were as follows: P1 (negative), P2 (trace to 1+ [30 
mg/dl]), and P3 (30-300 mg/dl) and P4 (> 300 mg/dl). 
Albuminuria was defined as urine albumin excretion between greater than 15 mg/dl (P2) and 
300 mg/dl (P4). Microalbuminuria was defined as urine albumin concentration of 30-
300mg/dl in spot morning. Macroalbuminuria/proteinuria was defined as urine albumin 
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concentration greater than 300mg/dl in spot morning urine (Levey et al., 2005; Nelissen et 
al., 2014). 
 
c) Electrocardiography  
A 12-lead ECG was performed to all patients using the Schiller MAC 600 system. ECG-LVH 
by voltage was based on Sokolow-Lyon criteria, where the sum of SV2 + RV6 in males of ≥ 
40 mm and females of ≥ 35 mm and RI ≥ 12mm (Sokolow et al., 1949).  
 
d) Transthoracic Echocardiography 
Focused transthoracic echocardiography was performed by the supervisor (AOM), in the 
presence of the candidate. Subjects were examined using standard parasternal, short-axis 
and apical views using a commercially available Philips HD7 Diagnostic Ultrasound System 
(Figure 3.1). Under this focused protocol left atrial to initial aorta ratio and shortening fraction 
(MFS) were calculated, while left ventricular ejection fraction (LVEF) was visually assessed. 
The measurements were made according to the American Society of Echocardiography 
(Sahan et al., 1978). Abnormal LV diastolic function (abnormal LV relaxation) was defined by 
the ratio A-wave/E-wave > 1. Hypertensive cardiac damage was defined by fractional 
shortening below 25% and left atrial enlargement (LAE). The definition of atrial enlargement 
is done based on a left atrium bigger than the aorta diameter (Brown et al., 1974). Aortic 
enlargement was defined as aortic root dimension above 40 cm (Brown et al., 1974). 
 
 




3.1.5. Statistical Analysis 
3.1.5.1. Data Analysis 
Data were entered into an Excel database and analysed using SPSS software version 20.0 
(SPSS Inc, Chicago, Illinois, USA). Descriptive analysis of the variables was performed to 
process the data as tables (cross-tabulations). Normal distributed continuous variables are 
represented as the means and standard deviation (SD), and non-Gaussian distributed 
variables as the median. Categorical variables were described using frequency tables 
(percentages).The independent Student’s t -test was used for continuous variables and Chi-
square tests were used to assess significance. Discrete variables were analysed via odds 
ratios with 95% confidence intervals. A (two-sided) P-value < 0.05 was considered 
statistically significant. 
 
3.1.6. Implementation Issues  
While the study started in July 2015 recruitment took place in two phases, due to an 
interruption from February 2016 to April 2016, related to funding limitations. Patients were 
recruited until November 2016 with the last follow-up completed in May 2017. Owing to the 
need to fulfil training courses and participation in scientific congresses the candidate had 
some support from colleagues from the National Health Institute to follow up the patients. 
 
3.1.7. Ethical Issues  
The study protocol was evaluated and approved by the National Mozambican Ethics 
Committee (approval reference number: 38/CNBS/16). Written informed consent was 









CHAPTER 4: RESULTS 
 
4.1.  Results: Demographic and Clinical profile of subjects 
4.1.1. Demographic data 
4.1.1.1. Socio-Demographic data of 116 subjects studied 
We have recruited 120 subjects with severe and/or complicated hypertension, of which four 
(3.3%) were excluded due to two were out of Maputo Province and two removed the 
informed consent for personal reasons. Thus only 116 subjects are included in the analysis. 
Most patients were black Africans (n=111 [95.7%]), and the study population contained more 
women (n=81 [70%]) than men. Women were slightly younger than men (mean 57 [SD 13] 
vs 59 [13] years); with 18 (15.5%) of 116 subjects younger than 44 years. Sixty-nine (59.5%) 
subjects were married, 31 (26.7%) were widows, 9 (7.8%) were single and only 4 (3.4%) 
were divorced/separated. Regarding the level of education, 20 (17.2%) did not have any 
formal education and only 4 subjects (3.4%) completed higher education. Fifty-four subjects 
(46.6%) did not have any occupation (jobless) and 21 (18.1%) were traders (Table 4.1).  
 
 












Mean age. Years ± SD 57.49 ± 12.82 58.69 ± 13.26 56.98 ± 12.68 
Median age. Years 58 61 57 
18-44 years 18 (15.5) 6 (17.1) 12 (14) 
45-54 years 30 (25.9) 4 (11.4) 26 (32.1) 
55-64 years 32 (27.6) 13 (37.1) 19 (23.5) 
≥ 65 years 36 (31.0) 12 (34.3) 24 (29.6) 
Race  
Black 111 (95.7) 33 (94.3) 78 (96.3) 
Asian  5 (4.3) 2 (5.7) 3 (3.7) 
Level of education    
None 20 (17.2) 1 (2.9) 19 (23.5) 
Primary 73 (62.9) 22 (62.9) 51 (63.0) 
Secondary 19 (16.4) 9 (25.7) 10 (12.3) 
Higher 4 (3.4) 3 (8.6) 1 (1.2) 
Status Marital    
Single 9 (7.8) 3 (8.6) 6 (7.4) 
Married 69 (59.5) 29 (82.9) 40 (49.4) 
Divorced 7 (6.0) 1 (2.9) 6 (7.4) 
Widower 31 (27.7) 2 (5.7) 29 (35.8) 
Occupation    
Jobless 54 (46.6) 3 (8.6) 51 (63.0) 
Traders 21 (18.1) 4 (11.4) 17 (21.0) 
Housemaid 4 (3.4) 0 (0.0) 4 (4.9) 
Guards 3 (2.6) 3 (8.6) 0 (0.0) 
Teachers 2 (1.7) 2 (5.7) 0 (0.0) 
Pensioners 7 (6.0) 7 (22.6) 0 (0.0) 
Drivers 3 (2.6) 3 (8.6) 0 (0.0) 
Others 21 (18.1) 12 (34.3) 9 (11.1) 




Figure 6: Level of education by sex of 116 subjects enrolled in the study. 
 
 
Figure 7: Occupation by sex of 116 subjects enrolled in the study. 
 
4.1.2. Clinical and Laboratory characteristics of subjects 
Self-reported established CVD and complications was 47.4% (55 of 116), where 23 (19.8%) 
subjects had a previous/present history of cerebrovascular disease (stroke) or transient 
ischaemic attacks and 22 (18.9%) had a previous/present history of heart failure. 
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4.1.2.1. Self-Reported Risk Factors 
As shown in Table 4.2 the frequency of self-reported diabetes mellitus was 8.6% (11.1% in 
women and 2.9% in men). The frequency of smoking was 6.9% (all the cigarette smokers 
were men) and that of alcohol consumption was 47.4% (55 of 116). The history of alcohol 
consumption in men had a significantly higher difference (p=0.001) when compared with 
women. The physical activity below the recommended levels was reported by 109 subjects 
(93.9%). The family history of cardiovascular disease (HTN, stroke and/or myocardial 
infarction) was present in 58 (50.0%) subjects. 
 







Personal history of DM 10(8.6) 1(2.9) 9(11.1) 0.278 
History of stroke or TIA 23(19.8) 10(28.6) 13(16.0) 0.121 
History of HF 22(18.9) 6(17.1) 16(19.8) 0.742 
History of smoking 
(current or former) 
8(6.9) 4(11.4) 4(4.9) 0.450 
History of Alcohol 
consumption 
55(47.4) 25(71.4) 30(37.0) 0.001 
History of physical 
inactivity 
109(93.9) 33(94.3) 76(93.8) 0.924 
Family history of CVD  58(50.0) 15(42.9) 43(53.1) 0.492 
CVD Cardiovascular disease; DM Diabetes Mellitus; HF Heart Failure; TIA transient ischemic attack. Significant 
P values (< 0.05) in bold. 
Table 6: Self-reported risk factors of 116 subjects enrolled in the study. 
 
4.1.2.2. Risk Factors Assessment 
The mean of BMI was 28.9 ± 5.9 kg/m2; Forty-eight (42.5%) subjects were obese (BMI ≥ 
30kg/m2). Mean of waist circumference was 97.1 ± 15.0 cm. Abdominal obesity was present 
in 13 out of 31 men (41.9%) and 59 out of 81 women (72.8%). The mean of body fat muscle 
was 37.9 ± 12.3 (27.8 ± 10.7 in men and 42.2 ± 10.3 in women) (p <0.001). The mean of 
body visceral Fat was 10.6 ± 4.9 and men had a significantly higher difference (13.1 ± 6.2 in 










BMI. kg/m2  ; N:113 28.9 (±  5.9) 28.3 (± 5.1) 29.1 (± 6.2) 0.479 
BM 25-29.9 Kg/m2 (35) 31% (13) 38.2% (22) 27.8% 0.273 
BMI ≥ 30kg/m2 (48) 42.5% (12) 38.2% (36) 45.6% 0.311 
WC; N:115 97.1 (± 15.0) 99.3 (± 14.6) 96.2 (± 15.2) 0.507 
WC - M: ≥102 cm 
13/31 (41.9%) 
W: ≥ 88 cm 
59/81 (72.8%) 
 
Fat Muscle; N:110 37.9 (± 12.3) 27.8 (± 10.7) 42.2 (± 10.3) <0.001 
Visceral Fat; N:110 10.6 (± 4.9) 13.1 (± 6.2) 9.5 (± 3.8) 0.003 
RM (kcal); N:110 1485.8 (± 222.6) 1652.7 (± 212.8) 1414.3 (± 186.5) <0.001 
Triglycerides (mg/dL) 
N: 110 
1.51 (± 1.1) 1.4 (± 0.8) 1.6 (± 1.2) 0.507 
 TG > 1.7 mg/dL (28) 25.5% (7) 20.6% (21) 27.6% 0.433 
Total cholesterol 
(mmol/L) N:109 
5.6 (± 1.5) 5.3 (± 1.2) 5.7 (± 1.6) 0.198 
Cholesterol > 4.9 
mmol/L 
(69) 63.3% (18) 54.5% (51) 67.1% 0.211 
Cholesterol > 5.2 
mmol/L 
(59) 54.1% (15) 45.5% (44) 57.9% 0.231 
Mean FBS N:116 6.1 (± 2.1) 5.9 (± 1.7) 6.1 (± 2.3) 0.714 
FBS ≥ 7.0mmol/l (23) 19.8% (7) 20.0% (16) 19.8% 0.976 
Serum uric acid 
(mg/dl); N:114 
387 (± 120.8) 421 (± 97.8) 371 (± 127.2) 0.025 
FBS Fasting blood sugar; TG Triglycerides; WC Waist circumference. Significant P values (< 0.05) in bold. 
Table 7: Risk factors assessment of 116 subjects enrolled in the study. 
Regarding biological markers mean total serum cholesterol was 5.6 ± 1.5, 69 of 109 (63.3%) 
subjects had hypercholesterolemia (cholesterol above 4.9mmol/L) and 54.1% had 
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dyslipidaemia (cholesterol above 5.2mmol/L). Mean of triglycerides blood level was 1.5 ± 1.1 
mg/dL and 28 of 110 (25.5%) subjects had hypertriglyceridemia (TG above 1.7 mg/dL). 
Mean of fasting blood sugar 6.1 ± 2.1 mmol/L and 23 (19.8%) had diabetes (FBS above 7.0 
mmol/L). The mean of serum uric acid was 387 ± 120.8 mg/dl (421 ± 97.8 in men and 371 ± 
127.2 in women) (p=0.025). 
4.1.2.3. Previous anti-hypertensive therapy 
Table 4.4 shows that 93 subjects (80.2%) reported being on antihypertensive drugs for the 
three months preceding entry in the study. In the screening, none of those who reported 
being on antihypertensive therapy had their BP controlled to < 140/90 mmHg. 
Variable % 
Detection of HTN  
Previously detected (94) 81.0 
Newly detected (22) 19.0 
Treatment of hypertension  
No treatment (23) 19.8 
Current treatment (93) 80.2  
Number of antihypertensive drugs  
1 (39) 33.6 
2 (34) 29.6 
3 (17) 14.7 
4 (4) 3.4 
≥ 4  (0); 0.0 
Type of antihypertensive drug  
Diuretics  (91) 97.8  
Calcium channel blockers (40) 43.0 
Angiotensin converting enzyme inhibitors (34) 36.6 
Angiotensin II antagonists (0) 0.0 
Beta-Blocking agents (7) 7.5 
Alpha-adrenergic antagonists (1) 1.1 
Centrally acting agents (1) 1.1 




The antihypertensive drugs used (either alone or in combination) included thiazide diuretics 
in 97.8% (91 of 93), calcium channel blockers in 43.0% (40 of 93), 36.6% (34 of 93) ACE 
inhibitors, and 7.5% (7 of 93) Beta-Blockers agents.  
We found 80.2% (93 of 116) subjects were receiving antihypertensive drugs, which 33.6% 
were receiving only one drug, 29.6% 2 drugs, 14.7% 3 drugs and only 3.4% were receiving 4 
drugs. None of the subjects investigated had been receiving more than 4 drugs. 
 
 
Figure 8: Type of antihypertensive drug of 116 subjects enrolled in the study. 
 
4.1.2.4. Previous therapy for co-morbidities 
Table 4.5 shows that 48. 3% (56 of 116) of the study population were receiving others 
treatments. For example, 12.5% (7 of 56) subjects were receiving antidiabetics, 16.1% (9 of 
56) antiplatelet (Aspirin), 37.5% (21 of 56) antiretroviral therapy, and 7.1% (4 of 56) were 










Subjects receiving other treatments (56) 48.3 
Antidiabetics (7) 12.5 
Digitals (Digoxin) (7) 12.5 
Antiplatelet (Aspirin %) (9) 16.1 
Anti-inflammatory (3) 5.4 
Nonsteroidal anti-inflammatory  (4) 7.1 
Antidepressants (1) 1.8 
Antiretroviral therapy (21) 37.5 
Anti-TB therapy (4) 7.1 
Table 9: Previous therapy for co-morbidities of 116 subjects enrolled in the study. 
 
4.1.2.5. Physical Examination 
The mean values of SBP and DBP were 192.4 (SD ± 23.6) and 104.2 (SD ± 15.2) mmHg, 
respectively. SBP and DBP did not vary significantly according to the gender (Table 4.6). 







Mean Heart rate (bpm) 79.6 (± 14.7) 77.4 (± 15.9) 80.5 (± 14.1) 0.294 
HR ≥ 100 bpm (10) 8.6% (2) 5.7% (8) 9.9% 0.721 
SBP (mmHg) 192.4 (± 23.6) 191 (± 22.3) 192.7 (± 24.3) 0.827 
DBP (mmHg) 104.2 (± 15.2) 104.1 (± 16) 104.3 ± 15.2 0.932 
Cervical murmur (47) 40.5% (10) 28.6% (37) 45.7% 0.085 
JVP  (17) 14.7% (4) 11.4% (13) 16.0% 0.583 
Congestion pulmonary (8) 6.9% (3) 8.6% (5) 6.2% 0.696 
Isolated ectopic beats (41) 35.3% (15) 42.9% (26) 32.1% 0.266 
3rd heart sound (4) 3.4% (0) 0.0% (4) 4.9% 0.314 
Mitral regurgitation (29) 25.0% (8) 22.9% (21) 25.9% 0.726 
Aortic regurgitation (20) 17.2% (6) 17.1% (14) 17.3% 0.985 
Hepatomegaly  (19) 16.4% (6) 17.1% (13) 16.0% 0.881 
Oedema peripheral (28) 24.1% (12) 34.3% (16) 18.8% 0.093 
BMI Body mass index; DBP Diastolic blood pressure; HR Heart rate; JVP Jugular venous pressure; SBP Systolic 
blood pressure. BPM beats per minute. Significant P values (< 0.05) in bold. 
Table 10: Physical examination of 116 subjects enrolled in the study. 
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Regarding clinical signs of HF at the time of recruitment, 10 (8.6%) subjects had a heart rate 
above 100 beats per minute (bpm), 17 subjects (14.7%) had high jugular venous pressure, 8 
(6.9%) had congestion pulmonary, 19 (16.4%) had hepatomegaly and 28 (24.1%) had 
oedema peripheral. On cardiac auscultation, 4 (3.4%) had a third murmur and 41 (35.3%) 
had isolated ectopic beats. Cervical murmur was present in 47 (40.5%) subjects. 
 
 
4.1.2.5.1. Severity of hypertension 
Table 4.8 shows that 8 (6.9%) subjects were in HTN grade 1 (SBP 140-159 or DBP 90-99 
mmHg with presence of OD), 29 (25%) were in HTN grade 2 (SBP 160-179 or DBP 100-109 
mmHg) and 79 (68.1%) subjects were in HTN grade 3 (SBP ≥ 180 or DBP ≥ 110 mmHg). 
Isolated systolic hypertension (SBP ≥ 140 and DBP < 90 mmHg) was present in 19 (16.3%). 
 







HBP grade 1 8 (6.9) 1 (2.9) 7 (8.6) 0.281 
HBP grade 2  29 (25) 11 (31.4) 18 (22.2) 0.599 
HBP grade 3  79 (68.1) 23 (65.7) 56 (69.1) 0.426 
Isolated systolic HTN  19 (16.3) 2 (5.7) 17 (21.0) 0.055 
DBP Diastolic blood pressure; SBP Systolic blood pressure. HTN Hypertension. Significant P values (< 0.05) in 
bold. 






Figure 9: Classification of severity HTN by sex of 116 subjects enrolled in the study. 
 
4.1.2.6. Relevant Biological Profile 
Table 4.7 shows that mean of creatinine was 109.9 ± 81.7 umol/L. The creatinine levels 
greater than 100 umol/L in men had statistically higher difference than women (p<0.001). 
Mean of eGFR was 79.7 ± 33.8. Using the K/DIGO classification, 36.2% had glomerular 
filtration rate of 90 ml/min or above and 27 of 116 (23.2%) had impaired GFR (eGFR below 
than 60 ml/min per 1.73 m2). 
Thirty-one (26.7%) of all subjects had anaemia (HGB < 12 mg/dl in women and HGB < 13 in 
men). The anaemia was significantly higher in women (37% vs 2.9%) than men (p<0.001), 
and median of iron was 14.8 ± 8.1 umol/L. Twenty-two subjects (19%) had HIV infection and 



















Creatinine umol/L (N:116) 109.9 ± 81.7 124.3 ± 69.7 103.6 ± 86.1 0.211 
Creatinine ≥ 100 umol/L 44 (37.9) 23 (65.7) 21 (25.9) <0.001 
eGFR (ml/min per 1.73 m2)  79.7 ± 33.8 73.8 ± 24.4 82.3 ± 37.0 0.217 
eGFR ≥ 90 ml/min per 1.73 m2 42 (36.2) 7 (20) 35 (43.2) 0.017 
eGFR < 60 ml/min per 1.73 m2 27(23.2) 10 (28.6) 17(21.0) 0.375 
GGT IU/L (N:105) 49.2 ± 45.1 56.5 ± 52.7 46.2 ± 41.7 0.276 
HGB (gr/dl) N:116 12.9 ± 2.1 14.6 ± 1.7 12.3 ± 1.8 <0.001 
Haematocrit (%); N:116 39.9 ± 6.1 44.5 ± 5.6 39.9 ± 5.2 <0.001 
Anaemia (HGB< 12 gr/dl)  31 (26.7) 1 (2.9) 30 (37.0) <0.001 
Severe anaemia (HGB< 8) 1 (0.9) 0 (0.0) 1 (1.2)  
Iron (umol/L) N:102 14.8 ± 8.1 15.5 ± 9.4 14.5 ± 7.6 0.562 
HIV positivity N:116 22 (19.0) 5 (14.3) 17 (21.0) 0.291 
CD4 (cells/mm3) N: 20 620.8 ± 578.8 557 ± 325.8 642 ± 649 0.785 
eGFR Estimated glomerular filtration rate; GGT Gamaglutamiltransferase; HGB Haemoglobin. Significant P 
values (< 0.05) in bold.  
Table 12: Biological profile of 116 subjects enrolled in the study. 
 
4.1.2.7. Electrocardiography characteristics of 113 subjects 
Table 4.9 shows that 103 subjects (88.8%) were in sinus rhythm. The sinus rhythm was 
more frequent in women (p=0.0409 than men. The most common ECG abnormalities were 
left ventricular strain pattern found in 57 (50.4%) subjects. Nine (7.9%) subjects had atrial 
fibrillation and 5 (4.4%) had bundle branch block. 







12-lead ECG findings  
Sinus rhythm 103(88.8) 30(90.9) 73(91.2) 0.040 
Atrial fibrillation 9(7.9) 3(9.1) 6(7.5) 0.119 
LVH 57(50.4) 20(60.6) 37(46.3) 0.165 
Bundle branch block 5(4.4) 2(6.1) 3(3.8) 0.628 
LV Left ventricular; Significant P values (< 0.05) in bold. 
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Table 13: Electrocardiographic findings in 116 subjects enrolled in the study. 
4.1.2.8. Echocardiography characteristics of one-hundred and three subjects 
The mean of left ventricular ejection fraction was 70.4 ± 13.5 (Table 4.10) and the mean 
shortening fraction was 36.1 ± 10.3; Nineteen subjects (18.4%) had systolic dysfunction 
(MFS < 25%).  







Echocardiographic findings  
Mean LVEF 70.4 ± 13.5 67.6 ± 14.3 71.6 ± 13 0.168 
MFS 36.1 ± 10.3 33.7 ± 10.2 37.2 ± 10.3 0.121 
Systolic dysfunction 19(18.4) 9(28.1) 10(14.1) 0.083 
LAE  (LA/AO) >1 87(84.5) 26(81.3) 61(85.9) 0.545 
Significant aortic enlargement 7(6.8) 5(15.6) 2(2.8) 0.029 
Diastolic dysfunction 53(51.5) 19(59.4) 34(47.9) 0.064 
AO aorta; LA Left atrial; LAE Left atrial enlargement; LVEF Left ventricular ejection fraction; MFS Midwall 
fractional shortening; Significant P values (< 0.05) in bold.  
Table 14: Echocardiographic findings in 116 subjects enrolled in the study. 
 
4.1.2.9. Frequency of Target organ damage 
The most frequent TOD in this population were left atrial enlargement in 87 (84.5%) with 
atrial fibrillation in 9 (7.9%), left ventricular hypertrophy in 57 (50.4%), hypertensive 
retinopathy in 30 (26. 3%) and renal damage in 29 (25.7%) subjects (Table 4.11). 
Some form of albuminuria was found in 29 subjects (25.7%). Microalbuminuria was present 
in 17 (15.0%) subjects and 1.8% had macroalbuminuria/proteinuria. 
Grade 1 hypertensive retinopathy was present in 0.9 % (1 of 114) of the study population, 
and the commonest retinopathy was grade 3 (13.2%) followed by grade 2 (12.3%). None of 







Target-organ damage  Number  Prevalence (%) 
TOD  38.5 
LVH 57/113 50.4 
LAE 91/103 84.5 
Atrial Fibrillation 9/113 8.0 
Hypertensive Retinopathy  30/114 26.3 
Grade 0 84/114 73.7 
Grade 1 1/114 0.9 
Grade 2 14/114 12.3 
Grade 3 15/114 13.2 
Grade 4 0 0.0 
Albuminuria 29/113 25.7 
Negative 84/113 74.3 
Trace albuminuria (15-30 mg/dl) 10/113 8.8 
Microalbuminuria (30-300 mg/dl) 17/113 15.0 
Macroalbuminuria (> 300 mg/dl) 2/113 1.8 
K/DIGO CKD stages   
Stage 1 GFR ≥ 90 42 36.2 
Stage 2 GFR 60-89 47 40.5 
Stage 3 GFR 30-59 17 14.7 
Stage 4 GFR 15-29 5 4.3 
Stage 5 < 15 5 4.3 
LVH = Left ventricular hypertrophy; LAE = Left atrial enlargement. 
Table 15: Frequency of different forms of TOD in 116 subjects enrolled in the study. 
 
4.1.2.10. Comparison of RF profile at the baseline and 6-months of follow-up 
Table 4.12 shows that mean values of SBP and DBP on 6-month follow-up were 151 (SD ± 
26.63) and 82.88 (SD± 12.69) mmHg after they received (more) intensive antihypertensive 





Variable At baseline 
(%) 
After 6 months 
(%) 
SBP Control  192.4 ± 23.6 151 ± 26.6 
DBP Control 104.2 ± 15.2 82.9 ± 12.7 
SBP < 140 mmHg 0 (0.0) 37 (37.4) 
DBP < 90 mmHg 19 (16.4) 67 (67.7) 
BMI ≥ 30kg/m2 48 (42.5) 35 (35.7) 
eGFR < 60mil/min per 1,73 m2 27 (23.2) 15 (15.8) 
Cholesterol> 4,9 mmol/L 69(63.3) 55 (57.6) 
TG > 1,7 mg/dl 28 (25.5) 19 (20) 
FBS ≥ 7.0 23 (19.8) 9 (9.5) 
BMI Body mass index; DBP Diastolic blood pressure; eGFR Estimated glomerular filtration rate; FBS Fasting 
blood sugar; SBP Systolic blood pressure; TG Triglycerides. Significant P values (< 0.05) in bold. 
Table 16: Comparison of BP controls and risk factors between baseline and follow-up of 
subjects enrolled in the study. 
 
4.1.2.11. Frequency of new events during the six-month follow-up  
Table 4.13 shows that 4 (3.4%) subjects had new events of stroke, 2 (1.7%) had a new 
event of heart failure and 4 (4.2%) had a new event of CKD over 6 months. Twelve (10.3%) 
subjects had a history of hospitalisations and 10 (8.6%) death. 
 
Target-organ damage  Number of cases at 
baseline (%) 
Number of new events 
over 6 months (%) 
Stroke/TIA 23(19.8) 4 (3.4) 
Heart Failure 22(18.9) 2 (1.7) 
Renal Damage 27(23.2) 4 (4.2) 
Hospitalisations - 12 (10.3) 
Deaths - 10 (8.6) 
GFR Glomerular filtration rate; TIA Transient ischaemic attack. 





4.1.3. Summary of Results 
The main findings in this study at first presentation were: 
 71% patients are less than 65 years old; 15.5% are less than 44 years; 68.1% 
presented in grade 3 HTN; 26.7% had anaemia and 19% were HIV positive;  
 80.1% had limited formal education (17.2% had never attended school and 62.9% 
had not completed the primary level); 64.7% had no fixed payday (46.6% 
unemployment and 18.1% informal traders);  
 At baseline there was a high frequency of dyslipidaemia (54.1%), self-reported 
alcohol consumption (47.4%), obesity (42.5%), cervical murmur (40.5%), and type 2 
diabetes (19.8%); 
 47.4% had already established cardiovascular complications at baseline, of which 
50.4% had LVH, 18.4% systolic dysfunction, 7.9% atrial fibrillation;  
 23.2% had overt CKD (GFR below than 60 ml/min); 25.7% had albuminuria, 15% 
microalbuminuria and 2% had overt proteinuria; 
 26.3% had hypertensive retinopathy, the majority with grade 2 and 3 retinopathy  
 4 patients were lost to follow up; 3 patients travelled out of Maputo Province but were 
assessed by a phone call and are in good health.  
 
Over 6-month follow-up: 3.4% patients had had a new stroke and 1.7% had a new 










CHAPTER 5: DISCUSSION  
 
5.1. Discussion 
In this predominantly young population of African origin population, a high frequency of risk 
factors to CVD such as obesity, dyslipidaemia and diabetes was found. Importantly, there 
was a high frequency of established cardiovascular and other target-organ damage at 
baseline, and on six months follow-up there were high rates of hospitalizations and death.  
This study confirms that in our country the majority of patients develop the disease at a 
young age. Almost three-quarters of all subjects (71%; 80 of 116) had less than 65 years of 
age, and 15.5% of them were younger than 44 years. Similar findings have been reported in 
other studies in SSA (Olack et al., 2015; Nelissen et al., 2014; Oladapo et al., 2012; Addo et 
al., 2009). It is of particular interest that in this population with severe HTN there was a high 
frequency of RF such as obesity, dyslipidaemia, diabetes, anaemia and HIV infection, which 
constitute an additional risk for developing early TOD, particularly cardiovascular 
complications (Nelissen et al., 2014), and may explain the hospitalisations and death in this 
population (Redon et al., 2016). 
Almost two-thirds of the patients (64.7%) had no fixed payday (46.6% were unemployed and 
18.1% traders), an expected finding in peri-urban settings of low-income countries such as 
Mozambique. Low and erratic family income may have determined the mode of presentation 
of these patients, which had advanced disease and several complications. In concordance 
with other countries in the SSA region, Mozambique has a low percentage of people with 
health insurance, related to the high rates of unemployment (Nulu S et al., 2016; Nelissen et 
al., 2014). Low insurance rates may have contributed to lower treatment coverage and BP 
control in this study population, as shown by other authors (Ibrahim and Damasceno, 2012; 
Hendriks et al., 2012; Kayima et al., 2013; Nulu S et al., 2016). Other factors that may have 
contributed for presentation with severe disease are the high proportion of subjects living 
without a partner (single/separated and widows) and the high percentage of illiteracy (only 
19.9% had the primary level completed). High adult illiteracy rates have been reported in 
developing countries (Nelissen et al., 2014; Ibrahim and Damasceno, 2012; WHO, 2010). 
Although no questions regarding income were asked, illiteracy, loneliness and poverty are 
known determinants of uncontrolled BP, by leading to poor adherence to hypertensive 
treatment, stress and depression, especially in elderly subjects (Anand et al., 2007; Ibrahim 
and Damasceno, 2012; Vaidya et al., 2013; Maatouk et al., 2016). This socio-demographic 
characteristic of this population influences understanding of the importance of adequate and 
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regular medication and needs to be taken in to account when designing health education 
strategies and policies. 
Past history and Risk Factors 
Our study corroborates the significant role of HTN in the causation of heart failure (Dokainish 
et al., 2016; Dokainish et al., 2015; Ojji et al., 2013; Damasceno et al., 2012; Sliwa et al., 
2008; Ayodele et al., 2005; Papademetriou, 2004). We found a high prevalence of 
established cardiovascular complications (47.4%), namely previous history of stroke/TIA 
(19.8%) and of congestive HF (18.9%). In Mozambique, there is an extremely low level of 
awareness and HTN control (Damasceno et al., 2009), and as a consequence, there is a 
high prevalence and incidence of stroke (Damasceno et al., 2010).  
The high prevalence of risk factors for NCDs found (high SBP, obesity, dyslipidaemia, type 2 
diabetes, anaemia, smoking and alcohol habits) may justify the high prevalence of stroke 
and HF in this population (O'Donnell  et al., 2016; Padrão et al., 2015; Damasceno et al., 
2012) and imposes a high economic burden of the health care system (Lemogoum D et al., 
2005). The frequency of overweight at 31% and that of obesity at 42.5% were higher than 
that obtained from the STEPS survey in Maputo-Mozambique, which found a prevalence of 
39.3% for overweight and 21.6% for obesity in urban general populations (Gomes et al., 
2010) and lower than 59% of Hi-Hi study based on the community and urban population in 
Cape Town-South Africa (Peer N et al., 2008). Gomes and co-workers found abdominal 
obesity in 22.6% of women and 4.5% of men in the urban area of Maputo City (Gomes et al., 
2011). Like the findings from previous studies (Sliwa et al., 2008; Gomes et al., 2011; 
Oladapo et al., 2012; Olack et al., 2015), we found a female predominance of obesity. This 
has become important in a culture where low weight is either associated with the stigma of 
malnutrition or HIV/AIDS, because it may render difficult to educate individuals about the 
dangers of excess weight (Pretorius et al., 2011).  
Self-reported type 2 diabetes (8.6%) and newly diagnosed type 2 diabetes mellitus 19% 
were both above the prevalence in those aged 25 to 64 years in Mozambique at 2.9% (Silva-
Matos et al., 2011) and the prevalence of diabetes in other regions of SSA (Manne-Goehler 
et al., 2016) at 5% (range 2-14%). In Nigeria studies in hypertensive subjects in the 
community the prevalence of type 2 DM was 9.6% in 2012 and 6.9% in 2014 (Oladapo et al., 
2012; Nelissen et al., 2014). In concordance with our finding, other study in Zambia reported 




In contrast, with the low dyslipidaemia reported in several studies in SSA, including previous 
studies in Mozambique (Damasceno et al., 2010; Nelissen et al., 2014; Kaze et al., 2016), 
we found that 54.1% of these high-risk subjects presented dyslipidaemia. The frequency of 
smoking in the studied population was 6.9%, similar to that reported in hypertensive subjects 
from Nigeria (Nelissen et al., 2014), but in higher than that reported from Cameron at 3.9% 
(Kaze et al., 2016). Finally, the frequency of alcohol consumption was very high (47.4%) 
when compared to previous studies (Nelissen et al., 2014; Olack et al., 2015; Kaze et al., 
2016) and men contributed more than women. 
Baseline Characterization 
Mean SBP levels (192.4 ± 23.6 mmHg) and DBP (104.2 ± 15.2 mmHg) were higher than 
those obtained in similar studies in Nigeria and Cameron (Oladapo et al., 2012; Nelissen et 
al., 2014; Kaze et al., 2016; Boivin et al., 2015). As expected 93 subjects had been receiving 
antihypertensive treatment; 97.8% were in treatment with thiazide diuretics associated with a 
potassium-sparing, followed by 43.0% with a calcium-channel blocker and 36.6% with ACE 
inhibitors; this latter drug is justified by the high prevalence of HF in our population. A 
comparable study found 91% (Peer N et al., 2008) and 86.1% (Oladapo et al., 2012) patients 
with treatment with thiazide diuretics, 10% (Peer N et al., 2008) and 15.6% (Oladapo et al., 
2012) with calcium channel blocker and 46% (Peer N et al., 2008) and 1.7% (Oladapo et al., 
2012) with ACE inhibitors. We also observed that 33.6% were receiving antihypertensive 
treatment with one drug, 29.6% with 2 drugs, 14.7% with 3 drugs and only 3.4% have been 
on treatment with 4 antihypertensive drugs.  
Hypertension, HIV infection and anaemia constitute main drivers of cardiovascular risk in 
SSA region, including Mozambique (Damasceno et al., 2012; Strijdom et al., 2017; Dillon et 
al., 2013; Chalmers et al., 2012; Kider et al., 2011; Triant et al., 2007). At baseline, 26.7% 
(31 of 116 patients) presented anaemia – only one had severe anaemia (HGB <8 mg/dl). 
The mean haemoglobin concentration was lower in women compared to men (12.9 vs. 14.6 
g/dl, p < 0.0001), is very common found in Mozambique where high rates of fertility, 
malnutrition and HIV infection are found (WHO, 2010; González  et al., 2017; Nhacolo et al., 
2006; Ogah et al., 2015). Anaemia is mainly caused by iron deprivation in the diet in our 
context (Aguilar et al., 2012), however in this study, women with anaemia presented serum 
iron slightly below the considered normal, but it was not statistically significant.  
Mozambique suffers one of the SSA highest burdens of HIV and AIDS, and since 2004 
started highly active antiretroviral therapy (Mozambique Ministry of Health, 2008). More 
recently, we adopted the “Prevent HIV, Test and Treat all” strategy, where all subjects tested 
positive for HIV should be initiated ARVs regardless of the CD4 value the according to WHO 
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guidelines (WHO, 2016). In this study, the frequency of HIV infection was 19% (22 of 116) 
slightly above the prevalence in general population, which was 13.2% in 2015 (IMASIDA 
Report, 2015). HIV infection can predispose to premature atherosclerosis through 
endothelial dysfunction, pro-inflammatory state and dyslipidaemia (Hsue et al., 2005). In our 
study, almost all subjects (21 of 22 subjects) had been receiving ARV therapy. Long-term 
survival is expected to increase in these treated patients, who will, therefore, have a higher 
risk of cardiovascular and metabolic complications (Luchuo et al., 2016). Additionally, 
infection with HIV has emerged as an important risk factor for stroke (Thakur et al., 2016; 
Benjamin et al., 2016; Walker et al., 2013), though most stroke cases reported amongst HIV 
patients were ischemic stroke (Thakur et al., 2016; Benjamin et al., 2016; Heikinheimo et al., 
2012).  
Nine subjects of our studied population have been receiving a low dose (100mg) of aspirin 
daily, but 23 of those had had previous stroke. Aspirin can reduce the risk of major 
cardiovascular events including stroke, particularly ischemic stroke (Thakur et al., 2016; 
Benjamin et al., 2016; Heikinheimo et al., 2012), and is widely available and very 
inexpensive in our context. While there is substantial evidence showing that low dose aspirin 
is beneficial in the secondary prevention of stroke, its benefit is less certain for primary 
prevention (Bhatt et al., 2010). In this studied population with uncontrolled BP aspirin may 
potentially increase the risk of having hemmoraghic stroke, a limiting factor to vulgarize the 
usage of low dose in our context (Luchuo et al., 2016). 
Target organ damage: We observed a high frequency of TOD of 38.5% in among adults 
with mostly severe HTN, corroborating reports from Nigeria and Ghana, which found 32% 
(Nelissen et al., 2014), and 43.1% (Oladapo et al., 2012) in Nigeria, and 48% in Ghana 
(Addo et al., 2009). HTN severity is a strong determinant for TOD (Nelissen et al., 2014) and 
is a public health problem in SSA, especially in African descent (Mensah et al., 1994; 
Howard G et al., 2013).  
Hypertensive heart disease: Heart damage was the main driver of TOD, followed by 
hypertensive retinopathy and kidney damage. More than half (50.4%) of the subjects had 
LVH according to Sokolow-Lyon criteria, a percentage higher than that found in community-
based studies in SSA, ranging from 15.9% to 33.3% (Addo et al., 2009),(Oladapo et al., 
2012) (Nelissen et al., 2014) and urban setting in South Africa at prevalence of 35% (Peer N 
et al., 2008). Like Boivin and co-workers, we found that men developed more LVH than 
women (Boivin JM et al., 2015). The high frequency of LVH found increases the risk of 
stroke or cerebrovascular disease, coronary heart disease, and HF and cardiac mortality 
(Catanzaro et al., 2002; McCullough 2002; Cuspidi et al., 2016). We recommend ECG to be 
used as a first-line marker for detection of subclinical cardiac damage in hypertensive 
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subjects in our setting, where 13 cardiologists exist for the whole  population of around 27 
million (Mocumbi, 2011), to reduce morbid cardiovascular events. 
LAE has adverse prognostic implications in hypertension. The high occurrence of LAE and 
atrial fibrillation in our population is also important to mention. Longitudinal studies have 
identified left atrial size as an independent predictor of an incident of atrial fibrillation (Okin et 
al., 2010), thrombo-embolic stroke (Nagarajaro et al., 2008), congestive HF and 
cardiovascular death (Laukkanen et al., 2005; Kim et al., 2015). Additionally, cross-sectional 
analyses conducted in patients with non-valve atrial fibrillation concluded that the extent of 
LA dilatation is related to the severity of ischaemic stroke (Kim et al., 2015).  
The mean left ventricular ejection fraction in our population was 70.4 ± 13.5. However, LV 
systolic dysfunction was observed in 18.4%. Similar studies in Nigeria (Salako et al., 2007; 
Ojji et al., 2009) and South Africa (Sliwa et al., 2008) found lower values. Like Ojji and Ogah 
in Nigeria, we found the lower frequency of LV systolic dysfunction in women compared to 
men (Ogah et al., 2015; Ojji et al., 2009).  
Echocardiography has become more available in Mozambique, but it is still restricted to a 
small number of referral centres of urban areas or to some tertiary centers in rural areas due 
to its costs and to the lack of expertise to perform the exams (Mocumbi, 2011; Mocumbi, 
2012). However, in tertiary centers where the machines are available, they are used 
primarily for obstetric indications by a nurse trained to screen high-risk pregnancies. In our 
context with a shortage of cardiologists and other specialists (Mocumbi et al., 2014; 
Mocumbi, 2011), we aim to decentralise the management of HBP and its complications to 
peripheral health facilities. We used abbreviated echocardiography to detect LAE and 
evaluate LV function in subjects with severe HTN. Our vision is that non-specialists medical 
and even non-medical staff (medical officers and nurses) could be trained to perform 
focused echocardiography to screen patients with severe HTN for cardiac damage, thus 
identifying those at high risk of poor outcomes.  
Renal Damage: Several studies showed that the most common cause of end-stage renal 
failure in younger individuals in SSA was hypertension (Banaga AS et al., 2015; Naicker S, 
2010; Diouf B et al., 2000). Albuminuria was present in 25.7% (29 of 113) of the subjects, 
using dipstick albuminuria method confirming the vulnerability of black patients to 
hypertensive kidney disease (Weber et al., 2014) and risk of chronic renal failure. The 
frequency of microalbuminuria (15.0%) was higher than that reported in Nigeria (12.3%) 
(Oladapo et al., 2012) and lower than values found in SSA regions – 26.9% in Zambia 
(Rasmussen JB et al., 2016), 32.3% (Busari et al., 2011) and 37% (Salako et al., 2007) in 
Nigeria and 39.3% in Cameroon (Kaze et al., 2016), and other studies done in North 
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America (21.6%) and Europe (16.8%) (Petrie et al., 2016). The occurrence of 
macroalbuminuria (1.8%) was similar to that found in Nigeria (2.0%) (Salako et al., 2007) 
and much higher values reported from Zambia Ghana and Nigeria, which were 8.9% 
(Rasmussen JB et al., 2016), 13.4% (Addo et al., 2009) and 15.2% (Oladapo et al., 2012), 
respectively. 
Importantly, the frequency of impaired eGRF was higher compared to some studies in SSA 
region (Sani et al., 2014; Nelissen et al., 2014; Addo et al., 2009), as well as America and 
Europe (Petrie et al., 2016) where 23.2% of the subjects had impaired eGRF. These results 
show a high burden of kidney disease and call for efforts on prevention through adequate 
control of HTN.  
Hypertensive retinopathy: Thirty patients (26.3%) had hypertensive retinopathy, of which 
25% had grades 2 and 3; no grade 4 disease was found. The frequency of grade 3 
hypertensive retinopathy was higher than that found by Oladapo et al., 2012; Addo et al., 
2009; Salako et al., 2007 in similar populations. Despite, the frequency of hypertensive 
grade 3 being very high, it is in aligned with extremely low level of BP control in general 
population in Mozambique (Damasceno et al., 2009). Additionally, there is a risk of blindness 
in these individuals which is often neglected in our setting.  
This study highlights this simple, non-invasive, and accessible technique (funduscopic) as a 
tool to screen TOD in hypertensive patients in our context. We think that this tool can be 
used for risk-stratification at entry point of health unit (emergency and consultation), 
preferably done by general practitioners due to lack of specialists/ophthalmologists in our 
country. 
Clinical outcomes: Only 37.4% subjects had BP controlled at the end of follow up, 
confirming the low HTN control rates found in community-based studies (Damasceno et al., 
2009; Ibrahim and Damasceno, 2012; Hendriks et al., 2012; Kayima et al., 2013). The 
results are only slightly better than those found in other studies: 35.6% (Oladapo et al., 201), 
27.3% (Nelissen et al., 2014) and 15.2% (Addo et al., 2009), and potentially explains the 
poor outcomes found on follow up. Over the 6-months follow up the occurrence of stroke, HF 
and impaired GFR was 3.4% (4 of 116), HF was 1.7% (2 of 116) and 4.2% (4 of 95), 
respectively. The high numbers of people with uncontrolled HTN, diabetes mellitus, obesity 
and dyslipidaemia, LVH and LAE may explain the high stroke incidence (Wolf, 1985; Mazza 
et al., 2001; Nagarajaro et al., 2008; O’Neal et al., 2016) and its high in-hospital case fatality. 
A high incidence of stroke is known to occur in the Mozambican population (Damasceno et 
al., 2010). Finally, high frequency of hospitalisations and deaths was found in our cohort in 




We used a non-representative sample and were forced to do parcelled recruitment due to 
lack funding. We, therefore, acknowledge that the results cannot be extrapolated to the 
general population. However, this study was realized in a first referral hospital and therefore 
is important in understanding the profile of patients needing care at peripheral levels of the 
health system.  
We could not clearly define the type of stroke involved: ischemic, haemorrhagic or thrombo-
embolic, because we could not perform CT (computed tomography) scans or MRI in all 
patients.  
We did not perform NT-ProBNP and sST2 exams, because we did not have enough funds to 
conduct these cardiac biomarkers ELISA tests.  
Finally, echocardiography, funduscopic examination and urinalysis at 6 months would have 
been important to compare to baseline findings and precisely describe the outcomes, but 
this was not done due to reduced human resources and financial capacity. 
Regarding clinical evaluation 24-h ambulatory BP monitoring was not performed. We 
recognize that it would have been important to precisely assess the rate of BP control. For 
subjects with evidence of proteinuria (2+ or 3+) on the urine dipstick, we did not obtain a 
spot urine protein-to-creatinine ratio (mg per mg) in 24 hours which would be a more 
appropriate measure of CKD. Though we found a high incidence of poor outcomes, during 
this exploratory study we were not able to correlate those with a risk factor and clinical 
features at baseline. Large numbers and further data analysis will be necessary to reach this 
objective. 
The results we present on poor BP control do not allow us to draw any conclusion on 
adherence to anti-hypertensive treatment, an important factor that we did not explore. 
Further research needs to be done to understand why patients closely followed up had such 













CHAPTER 6: CONCLUSIONS AND PERSPECTIVES 
6.1. Conclusions and Perspectives 
6.1.1. Conclusions  
In this low-resourced urban setting of Africa severe and complicated HTN occurs in young 
people who present high-risk profile characterized by obesity, dyslipidaemia, diabetes and 
anaemia. Significant TOD is prevalent in the form of cardiac damage (including left 
ventricular dysfunction), kidney lesion (microalbuminuria and overt CKD), hypertensive 
retinopathy and stroke. Moreover, we found high case-fatality and hospitalisation rates on 
short follow-up, in accordance with low blood pressure control and high frequency of TOD. 
Our results highlight the urgent need for prevention of hypertension and its complications. In 
our resource-constrained setting we propose the design of algorithms for diagnosis, 
management and follow up of hypertension using non-invasive tests, that can be done by  
non-specialists, namely ECG to detect LVH, atrial fibrillation, and ischaemic changes; urine 
dipstick to detect microalbuminuria; funduscopic evaluation to discard hypertensive 
retinopathy; and, focused abbreviated echocardiographic evaluation to determine the 
presence of LAE and systolic dysfunction. This approach would not only stratify high-risk 
patients but also allow decentralization care to hypertensive subjects, allowing prevention of 
poor outcomes.  
 
6.1.2. Perspectives 
We aim to follow-up this research line to explore the usefulness of implementation of 
algorithms for risk stratification, diagnosis and management of hypertension and its 
complications. Such studies will include 24-h ambulatory BP monitoring, focused 
echocardiography performed by non-specialists and dissemination of the use of fundoscopy, 
as well as assess the efficacy and cost-effectiveness of TOD screening in Mozambique. 
Another important area of research will be the association between HIV infection and severe 
hypertension and its role as a risk factor for poor outcomes. 
Evaluation of determinants for poor control and adherence to antihypertensive drugs must 
also be carried out, to understand how we can improve BP control rates. These should 
include psychosocial tests to discard cognitive changes in hypertensive patients. 
Implementation science should also be developed on tailored strategies for health education 






Advocate for healthy public policy and a comprehensive national program for 
prevention and control of hypertension  
  
a. Design algorithms for diagnosis, management and treatment of arterial hypertension 
and other NCD risk factors 
Algorithms with simple information about diagnose, management and treatment can help the 
clinical staff to improve the health care provided to individuals with arterial hypertension and 
other NCD risk factors, mainly diabetes and dyslipidaemia. In this low-income setting, 
attempts should be improve early detection of hypertensive subjects; efforts may be directed 
particularly within the community, and managed appropriately before irreversible TOD and 
complications emerge. The National Program for the prevention and control of NCDs of 
MOH-Mozambique should take the lead in this process. 
 
b. Screening and risk-stratification protocols to identify high-risk individuals 
BP screening in asymptomatic individuals can assist in identifying high-risk individuals who 
would not otherwise seek treatment before developing other complications, but can also 
avoid overwhelming the fragile health infrastructure with individuals who have low levels of 
HBP that confer little risk of TOD. It identifies a spectrum of high- and low-risk individuals, 
which may be managed according to their risk. The National Program for the prevention and 
control of NCDs of MOH-Mozambique should promote the use of risk-stratification protocols 
available. 
 
c. Clinical staff training for HTN management and TOD screening 
Training of health professionals will play a role in assuring and proving a quality health care, 
treatment and follow-up. In our context, building capacity to address HTN and other risks 
factors for TOD, through decentralization of care to nurses and general physicians is very 
important. District-level nurses and generalist physician should be receive training in HBP 
diagnosis and management, as well as learn to identify and refer high-risk patients to higher 
levels of care. Integration of management of several RF in chronic disease consultations for 
HIV-positive subjects at health facilities would be a way of ensuring that most clinical staff 
are trained and, on the other hand, that all subjects seeking medical care are screened.  
TOD screening for renal damage, cardiovascular complications and other associated 
conditions (diabetes, hypercholesterolemia and gout) must be available at the lower level of 




d. Health education program in hospitals and communities 
Health education for hypertensive subjects (or with other NDCs) and their families should be 
done together with campaigns for increasing public awareness, educate physicians, as well 
as policies for reducing salt intake and promoting healthy lifestyles. In Mozambique, the 
population presents a limited level of education; therefore, more health education programs 
with audio-visual instruments should be created, eg. Speeches about HTN and RF 
(prevention, screening and importance of regular and adequate treatment) and forms to 
prevent their complications in local language in radio stations and public television channels. 
Pamphlets and mobile text messages can also be used. Health education in schools may 
provide knowledge and skills early in life, and lead to the adoption of healthy lifestyles from 
young ages, including regular checking of BP, physical activity and healthy dietary habits for 
obesity prevention. Additionally, policies to limit marketing of alcohol should be created. 
Finally, to prevent and control hypertension in Mozambique multi-sectoral approaches are 
needed, involving health, education, agriculture, transport, finance among others sectors. 
 
e. Access to medicines and regulations for the food industry 
Availability of medicines to all in public hospital pharmacies is as important as the regular 
intake by individuals to prevent TOD. Mozambique’s low socio-economic and formal 
employment levels determine weak purchasing power for medicines in private pharmacies. 
Universal health coverage principles determine that government has the responsibility to 
ensure that all citizens have continuous availability of low-cost generic medicines or free 
access to medicines for chronic conditions. Regulations for the food industry to the reduction 
of salt, sugar and fat, and increase the levels of fibre; and also potassium and calcium in 
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